Clinical Trials on Alzheimer's Disease

Final Scientific Program

Boston, November 1-4, 2017

www.ctad-alzheimer.com
Welcome ................................................................. p. 3
Keynote Speakers ................................................. p. 4
Lifetime Achievement Award .............................. p. 5
Program ................................................................. p. 6
  - Program at Glance ........................................... p. 6
  - Wednesday, November 1 ............................... p. 8
  - Thursday, November 2 ................................. p. 9
  - Friday, November 3 ...................................... p. 12
  - Saturday, November 4 ................................. p. 15
Poster sessions .................................................... p. 19
Gold Partners ....................................................... p. 43
General Information ............................................ p. 44
Conference Mobile App ................................. p. 47
Dear Colleague,

The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.

Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.

At CTAD 2017 several teams will report the results of their preclinical, Phase II and Phase III trials. This sharing of experiences converges towards a same goal: overcoming the hurdles and speed the development of effective treatments in AD.

Welcome to Boston!

Scientific Committee

Susan ABUSHAKRA (San Francisco)
Paul AISEN (San Diego)
Kaj BLENNOW (Molndal)
Merce BOADA (Barcelona)
Maria CARRILLO (Chicago)
Mony John DE LEON (New York)
Rachel DOODY (Basel)
Bruno DUBOIS (Paris)
Howard FELDMAN (San Diego)
Nich FOX (London)
Giovanni B. FRISONI (Brescia, Geneva)
Lutz FROELICH (Mannheim)
Serge GAUTHIER (Montreal)
Ezio GIACOBINI (Geneva)
Michael GRUNDMANN (San Diego)
Harald HAMPEL (Paris)
Takeshi IWATSUBO (Tokyo)
Ara KHACHATURIAN (Washington DC)
Zaven KHACHATURIAN (Washington DC)
Virginia LEE (Philadelphia)
Constantine G. LYKETSOS (Baltimore)
José Luis MOLINUEVO (Barcelona)
Jean-Marc ORGOGOZO (Bordeaux)
Ronald PETERSEN (Rochester)
Craig W. RITCHIE (Edinburgh)
Augustin RUIZ (Barcelona)
Robert RISSMAN (San Diego)
Stephen SALLOWAY (Providence)
Philip SCHELTENS (Amsterdam)
Lon SCHNEIDER (Los Angeles)
Eric SIEMERS (Philadelphia)
Peter SNYDER (Rhode Island)
Reisa SPERLING (Boston)
Yaakov STERN (New York)
Jacques TOUCHON (Montpellier)
John TROJANOWSKI (Philadelphia)
Bruno VELLAS (Toulouse)
Michael W. Weiner (San Francisco)
Gordon WILCOCK (Oxford)
Bengt WINBLAD (Stockholm)

Jacques Touchon MD, PhD
University
Hospital of Montpellier
France

Paul Aisen MD
Alzheimer’s Therapeutic Research Institute (ATRI)
University of Southern California (USC), San Diego, USA

Bruno Vellas MD, PhD
University
Hospital of Toulouse
France

Mike Weiner MD
University of California San Francisco (UCSF), USA
Rachelle Doody, MD, PhD

is the Global Head of Neurodegeneration in Product Development, Neuroscience at Roche Pharmaceutical Company and its US entity, Genentech. She holds a BA in English and MA/PhD in Cognitive Anthropology from Rice University (focus on the brain and language), and did her medical training at Baylor College of Medicine in Houston, Texas and McGill University in Montreal, Canada. She is board certified in Neurology and Psychiatry. Fieldwork experience includes studying cognition among non-literate Karen hill tribes in Northern Thailand.

Prior to joining Genentech/Roche in September, 2016, Dr. Doody was the Effie Marie Cain Chair in Alzheimer’s Disease Research at Baylor College of Medicine, in Houston, Texas where she had founded and directed the Alzheimer’s Disease and Memory Disorders Center over a period of 27 years. She is now Distinguished Professor Emeritus at Baylor. While at Baylor, she published over 200 original research articles primarily dealing with the diagnosis and treatment of Alzheimer’s disease and related neurodegenerative disorders, served on the steering committees for the National Institutes of Health-funded Alzheimer’s Disease Cooperative Study (ADCS) and Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the executive committee for the Alzheimer’s Therapeutic Research Institute (ATRI). Dr. Doody was the Principle Investigator for the Phase 2 and 3 development of donepezil (Aricept) which is now the most widely-used AD therapy globally, and worked with numerous biotech and pharma companies over a period of 25 years in the design and execution of treatment trials for cognitive and behavioral treatment of AD. She has contributed to efforts to globalize the diagnosis and treatment of AD, including advising on guidelines in China, Malaysia, South Korea and the Philippines, educating investigators throughout Europe and Asia on study design issues, and training investigators on outcome measures to support global studies.

In her role as a practicing Neurologist, Dr. Doody was elected to Best Doctors in America from 1996-2016. She has received many awards from professional and civic groups, including Distinguished Alumni Award from Rice University in 2009 and Distinguished Faculty Award from Baylor College of Medicine in 2011.

John Anthony Hardy, PhD

is a human geneticist and molecular biologist at the Reta Lila Weston Institute of Neurological Studies at University College London with research interests in neurological diseases.

Following his PhD, Hardy did postdoctoral research at the MRC Neuropathogenesis Unit in Newcastle upon Tyne, England and then further postdoctoral work at the Swedish Brain Bank in Umeå, Sweden where he started to work on Alzheimer’s disease. He became Assistant Professor of Biochemistry at St. Mary’s Hospital, Imperial College London in 1985 and initiated genetic studies of Alzheimer’s disease there. He became Associate Professor in 1989 and then took the Pfeiffer Endowed Chair of Alzheimer’s Research at the University of South Florida, in Tampa in 1992. In 1996 he moved to Mayo Clinic in Jacksonville, Florida, as Consultant and Professor of Neuroscience. He became Chair of Neuroscience in 2000 and moved to National Institute on Aging, Bethesda, Maryland, as Chief of the Laboratory of Neurogenetics in 2001. In 2007 he took up the Chair of Molecular Biology of Neurological Disease at the Reta Lila Weston Institute of Neurological Studies, University College London. On November 29, 2015, he was awarded the Breakthrough Prize.

Reisa A. Sperling, MD, MMSc

Director, Center for Alzheimer’s Research and Treatment
Professor of Neurology, Harvard Medical School
Director of Clinical Research, Memory Disorders Unit, Brigham and Women’s Hospital
Director, Neuroimaging Program, Massachusetts Alzheimer’s Disease Research Center

Reisa Sperling MD, MMSc is a neurologist, specializing in dementia and imaging research. Dr. Sperling’s research is focused on the early diagnosis and treatment of Alzheimer’s disease. Her recent work involves the use of functional MRI and PET amyloid imaging to study alterations in brain function during in aging and early Alzheimer’s disease. She is the Principal Investigator on multiple NIH and Foundation grants to study the neural basis of memory impairment in MCI and AD, and the relationship of amyloid deposition to memory function.

Pierre N. Tariot, MD

Director, Banner Alzheimer’s Institute, Research Professor of Psychiatry, University of Arizona College of Medicine

Dr. Tariot is Board Certified in Internal Medicine and Psychiatry, with added qualifications in geriatrics. He served as a Fellow at the National Institute of Mental Health and as faculty at the University of Rochester Medical Center. Since 2006, he has been at the Banner Alzheimer’s Institute in Phoenix, where he serves as Director. He has investigated the diagnosis, therapy and prevention of Alzheimer’s disease, and has published over 350 papers on these topics. Together with his colleague, Eric Reiman, he serves as co-director of the Alzheimer’s Prevention Initiative, an NIH-funded international program to study experimental therapies that may delay or even prevent the symptoms of Alzheimer’s in people at high imminent risk. He is a Research Professor of Psychiatry at the University of Arizona College of Medicine. His research affiliations include the NIA, the NIMH, and the Alzheimer’s Association.
Bruno Dubois, MD, PhD

Bruno Dubois is Professor of Neurology at the University Salpêtrière Hospital in Paris. He is Director of the “Institute for Memory and Alzheimer Disease” (IM2A) and of the Research INSERM Unit on “Cognition and Neuroimaging in Brain Diseases” at the ICM at the Salpêtrière Hospital. He is Coordinator of the National Reference Center for “Rare Dementias”; of the National Reference Center for “Young-Onset Alzheimer disease” and of the Center of Excellence for Neurodegenerative Disorders (CoEN) of Paris. He was involved in the elaboration of the Presidential Alzheimer Plan and he is in the Executive Committee of the Plan.

Professor Dubois completed his Neurology residency and a fellowship in Behavioral Neurology at the Salpêtrière hospital. He has published more than 500 peer-reviewed articles on anatomical and biochemical studies on the central cholinergic systems in rodents and humans, on human cognition with special reference to memory, executive functions and frontal lobe behaviors and on biomarkers in neurodegenerative disorders. He was co-chairing the task force on the criteria and guidelines for the diagnosis of Parkinson’s disease dementia under the auspices of the Movement Disorders Society. He leads an international working group of experts on the new criteria for Alzheimer Disease.

Bruno Dubois is member of the Académie Nationale de Médecine. He is “Chevalier de la Légion d’honneur”.

2017 Recipient of the CTAD Lifetime Achievement Award
PROGRAM AT GLANCE

Wednesday, November 1

4:00 – 4:30 p.m. Welcome from the Organizing Committee and Presentation of the CTAAD Lifetime Achievement Award
4:30 – 5:00 p.m. Keynote 1 - The Evolution of Preclinical Alzheimer’s disease: Implications for Prevention Trials
5:00 – 6:00 p.m. Late Breaking Oral communications
6:00 p.m. End of the Scientific Program
6:15 – 8:00 p.m. Turning Point Documentary

Thursday, November 2

8:30 – 10:00 a.m. Oral communications
10:00 – 10:30 a.m. Coffee Break and Poster Session
10:30 – 11:30 a.m. Oral communications
11:30 – 12:30 p.m. Symposium 1 - CTAD 2017 Statistical Workshop: Estimands and Primary Analyses in AD Clinical Trials
12:30 – 1:30 p.m. Lunch and Poster Session
1:30 – 2:30 p.m. Oral Communications
2:30 – 3:00 p.m. Keynote 2 - From Academy to Industry: Perspectives for Drug Trials in AD
3:00 – 4:00 p.m. Late Breaking Oral Communications
4:00 – 4:30 p.m. Coffee Break and Poster Session
4:30 – 5:30 p.m. Symposium 2 EPOCH Trial of the BACE1 Inhibitor Verubecestat for Mild-to-Moderate Alzheimer’s Disease
### Friday, November 3

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 – 10:00 a.m.</td>
<td><strong>Oral Communications</strong></td>
</tr>
<tr>
<td>10:00 – 10:30 a.m.</td>
<td>Coffee Break and Poster Session</td>
</tr>
<tr>
<td>10:30 – 11:00 a.m.</td>
<td><strong>Keynote 3</strong> - Genetic Aspects In Clinical Trials</td>
</tr>
<tr>
<td>11:00 – 12:30 p.m.</td>
<td><strong>Oral Communications</strong></td>
</tr>
<tr>
<td>12:30 – 1:30 p.m.</td>
<td>Lunch and Poster Session</td>
</tr>
<tr>
<td>1:30 – 2:30 p.m.</td>
<td><strong>Symposium 3</strong> - Importance of Serotonin in Alzheimer’s Disease Psychosis and the Potential Role of Pimavanserin</td>
</tr>
<tr>
<td>2:30 – 3:30 p.m.</td>
<td><strong>Late Breaking Oral Communications</strong></td>
</tr>
<tr>
<td>3:30 – 4:00 p.m.</td>
<td><strong>Oral Communications</strong></td>
</tr>
<tr>
<td>4:00 – 4:30 p.m.</td>
<td>Coffee Break and Poster Session</td>
</tr>
<tr>
<td>4:30 – 5:00 p.m.</td>
<td><strong>Keynote 4</strong> - Rationale, Design and Progress of the 3 Active Alzheimer’s Prevention Initiative Trials</td>
</tr>
<tr>
<td>5:00 – 6:00 p.m.</td>
<td><strong>Symposium 4</strong> - Results from the Phase 3 MINDSET STUDY: A Global, Double-Blind, Placebo-Controlled Study of Inteipidine in Mild-to-Moderate Alzheimer’s Disease</td>
</tr>
</tbody>
</table>

### Saturday, November 4

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 – 10:00 a.m.</td>
<td><strong>Oral Communications</strong></td>
</tr>
<tr>
<td>10:00 – 10:30 a.m.</td>
<td>Coffee Break and Poster Session</td>
</tr>
<tr>
<td>10:30 – 11:00 a.m.</td>
<td><strong>Late Breaking Oral Communications</strong></td>
</tr>
<tr>
<td>11:30 – 12:30 p.m.</td>
<td><strong>Symposium 5</strong> - Synaptic and Network Dysfunction in Alzheimer’s Disease (AD): Translational Insights and Therapeutic Opportunities</td>
</tr>
<tr>
<td>12:30 – 1:30 p.m.</td>
<td>Lunch and Poster session</td>
</tr>
<tr>
<td>1:30 – 2:15 p.m.</td>
<td><strong>Clinical Trials Prescreening Focus Panel</strong></td>
</tr>
<tr>
<td>2:15 – 3:15 p.m.</td>
<td><strong>Oral Communications</strong></td>
</tr>
<tr>
<td>3:15 – 4:15 p.m.</td>
<td><strong>Late Breaking Communications</strong></td>
</tr>
<tr>
<td>4:15 – 4:30 p.m.</td>
<td><strong>Closing Session</strong></td>
</tr>
</tbody>
</table>
Welcome from the Organizing Committee and Presentation of the CtaD Lifetime Achievement Award to Prof. Bruno Dubois
Jacques Touchon, Paul Aisen, Bruno Vellas, Mike Weiner

Keynote 1
The Evolution of Preclinical Alzheimer’s disease: Implications for Prevention Trials
Introduction: Bruno Vellas, MD, PhD, University Hospital of Toulouse, France
Reisa Sperling, MD Harvard Medical School - Center for Alzheimer Research and Treatment Brigham and Women's Hospital and Massachusetts General Hospital Memory Disorders Unit Boston, USA

Late Breaking Oral communications
Chairs: Rachelle Doody, Philip Scheltens

LBI - Utilizing a PK/PD model to enable design principles within the gantenerumab Phase 3 Graduate program
Rachelle Doody, MD PhD1, Ronald Gieschke, MD, PhD2, Daniel Serafin, PhD2, Sylvie Retout PhD2, Paul Delmar PhD1, Mirjana AdjeIovovic, PhD1, Danielle Abi-Saab, PhD1, Smiljana Milosavljevic-Ristic, MD, PhD1, Paulo Fontura MD, PhD1, Carsten Hofmann, PhD1

LB2 - Higher Dose Gantenerumab leads to Significant Reduction in Amyloid Plaque Burden - Results for the Marguerite and Scarlet Road Open Label Extension Studies
Gregory Klein, PhD1, Paul Delmar PhD1, Carsten Hofmann, PhD1, Mirjana AdjeIovovic, MD1, Danielle Abi-Saab, MD1, Smiljana Milosavljevic-Ristic, MD, Monika Baudler, PhD2, Paulo Fontura MD, PhD2, Rachelle Doody, MD2

LB3 - Efficacy and safety of S 47445, a modulator of AMPA glutamatergic receptors, in patients suffering from Alzheimer’s disease at mild to moderate stage with depressive symptoms.
Pueyo Maria, MD, PhD1, Bernard Katy, PhD, Breitin Sylvie, PharmD, PhD1, Goutefangeas Sylvie, MD1, Holthoff-Detto Vjera, MD1 and Robert Philippe, MD1

LB4 - Phase IIa study results with the glutaminylcyclase inhibitor PQ912 in early Alzheimer’s Disease
Philip Scheltens1, MD, PhD, Merja Hallihainen1, MD, PhD, Timo Grimmer1, MD, Thomas Duning1, MD, Alida A. Gouw1, MD, PhD, Paul Maruff7, BBSc (Hons), PhD, G. Caroline M. van Baal8, PhD, Suzanne Bruins8, MSc, Inge Lues9, PhD, Charlotte E. Teunissen10, PhD, Niels D. Prins11, MD, PhD

End of the Scientific Program
6 p.m.
6:15 - 8:00 p.m.

Turning Point Documentary
Please join filmmaker James Keach for a reception with refreshments

In the gripping new documentary “The Turning Point,” acclaimed filmmaker James Keach takes us inside the quest for the first medication that could treat the underlying process of Alzheimer’s disease, more than a century after Dr. Alois Alzheimer first described the brain disorder that slowly destroys memory and cognitive skills. Along the way, we meet the people behind these grand experiments, the scientists driven as much by personal conviction as professional innovation. We discover why medical science is never easy, often unpredictable and potentially perilous – and, as America’s preeminent scientist Neil deGrasse Tyson reminds us, always worth the pursuit.

The project was funded through an unrestricted grant by Eli Lilly and Company to Volunteers of America
Oral Communications

Chairs: Jeffrey Cummings, Kathryn V. Papp

**OC1 - A Phase 2a Exploratory Endpoint Trial in Mild-Moderate Alzheimer’s Disease of LMI1A-31-BH5 p75 neurotrophin receptor ligand.**

Franth M. Longo, MD, PhD; Manfred Windisch, PhD; Niels Andreassen, MD, Agneta Nordberg, MD, PhD

(1) Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, CA, USA; (2) NeuroSics GmbH, Graz, Austria; (3) Department of Neurology, Karolinska Institute, Stockholm, Sweden; (4) Center for Alzheimer’s Research, Karolinska Institute, Stockholm, Sweden

**OC2 - Tau Accumulation Observed using Repeated Tau PET Measures Predicts Cognitive Decline in Normal Elderly.**

Bernard Hansewuy, Beth Mormino, Alex Becker, Aaron Schultz, Jorge Sepulcre, Kathryn Papp, Heidi Jacobs, Jasmeer Chhatwal, Dorene Rentz, Reisa Sperling, and Keith Johnson

(1) Department of Radiology, Massachusetts General Hospital, Boston, MA, USA; (2) Department of Neurology, Cliniques Universitaires Saint-Luc, Brussels, Belgium; (3) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; (4) Center for Alzheimer’s Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

**OC3 - Clinical evaluation of [18F]-PI-2620, a next generation TAU PET agent in subject with Alzheimer disease and progressive supranuclear PALSY.**

Andrew Stephens, John Selby, Andre Mueller, Olivier Barret, Mathias Berndt, Jennifer Madonia, David Alagille, Hanno Schieferstein, Heiko Kroth, Santiago Bullich, Andrea Pfeiffer, Andreas Muhs, Gilles Tamagnan, Kenneth Marek, Ludger Dinkelborg

(1) Piramal Imaging, Berlin, Germany; (2) Molecular Neuroimaging, New Haven, USA; (3) AC Immune SA, Lausanne, Switzerland

**OC4 - Optimizing the Preclinical Alzheimer’s Cognitive Composite (PACC) with Semantic Processing: The PACC 5.**

Kathryn V. Papp, Dorene M. Rentz, PsysD, Irina Orlovsky MA, Reisa A. Sperling MD, Elizabeth C. Mormino PhD

(1) Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; (2) Department of Neurology, Massachusetts General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; (3) Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, USA

**OC5 - Can IT Help with the Screening for Alzheimer’s Disease Trials? From EHR to Web-Based Cognitive Tests and e-Consent.**

Peter Schuler, MD, Michael W. Weiner, MD, J. Wesson Ashford, MD, PhD, Bruno Vellas, MD, PhD

(1) UCSF, San Francisco, CA, USA; (2) ICON, Langen, Germany; (3) University Duisburg-Essen, Germany; (4) Stanford/VA Alzheimer’s Disease and Aging Clinical Research Centers, CA, USA; (5) VA Palo Alto Health Care System, CA, USA; (6) Stanford University, CA, USA

(7) University Hospital’s Department of Internal Medicine and Clinical Gerontology, Toulouse, France; (8) Toulouse Gérontopôle, Toulouse, France

**OC6 - Amyloid Beta Oligomers in Alzheimer’s Disease: a Missing Piece of the Alzheimer’s Puzzle.**

Jeffrey Cummings MD, Sandrine Andrieu MD, MPH, Philip Scheltens MD, PhD, Kaj Blennow MD, PhD, Petr Kocis PhD, John A. Hey PhD, A. Power, MD, Martin Tolar, MD, PhD, Susan Abushakra MD

(1) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada; (2) University of Toulouse, Toulouse, France

(3) VU University Medical Center, Amsterdam, Netherlands; (4) The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden

(5) Alzheimer’s Inc., Boston, MA, USA

Coffee Break and Poster Session (Georgian Room)

Oral Communications

Chairs: Rebecca E. Amargioli, Pierre-Jean Ousset

**OC7 - ABBV-8E12, a Humanized Anti-Tau Monoclonal Antibody for the Treatment of Early Alzheimer’s Disease: A 96-Week, Multiple Dose, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study.**


(1) AbbVie Inc; North Chicago, IL, USA; (2) C2N Diagnostics LLC; Saint Louis, MO, USA; (3) Washington University, St. Louis, MO, USA; (4) AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

**OC8 - Stratification of Pre-Symptomatic and Cognitively Normal Individuals using Polygenic Scoring.**

Maryam Shoai, PhD, Richard Pithee, PhD, Valentina Escott-Price, PhD, Simon M Laws, PhD, Harald Hampel, MD, PhD, Simone Lista, PhD, Rik Vanderberghe, Isabelle Cleynen, David Irwin, MD, Vivian Van Deerlin, MD, Greg Davidson, PhD, Virginia M.-Y. Lee, PhD, John Q. Trojanowski, MD, PhD, John Hardy, PhD, DSc

(1) UCL Institute of Neurology, London, United Kingdom; (2) Cuvox Ltd, UK, Oxford, United Kingdom; (3) Cardiff University, Cardiff, United Kingdom; (4) Edith Cowan University, and Cooperative Research Centre (CRC) for Mental Health, Perth, Australia; (5) AXA Research Fund & UPMC Chair, Paris, France; (6) Katholieke Universiteit Leuven, Leuven, Belgium; (7) Hospital of the University of Pennsylvania, Department of Neurology, University of Pennsylvania, Philadelphia; (8) Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia; (9) Ledcourt Associates, UK; (10) Centre for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia
OC9 - Objective Cognitive Decline in Preceding Years Relates to Self-Report on the Cognitive Function Index in the Harvard Aging Brain Study
Rebecca E. Amariglio PhD1,2, Rachel F. Buckley PhD2,4,5, Elizabeth C. Mormino PhD2,3, Dylan R. Kim MPH2, Gad A. Marshall MD2,3, Keith A. Johnson MD1,2,3, Dorene M. Rentz PsyD2,3, Reisa A. Sperling MD1,2,3

(1) Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA; (2) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; (3) Harvard Medical School, Boston, MA, USA; (4) Florey Institutes of Neuroscience and Mental Health, Melbourne, Australia; (5) Melbourne School of Psychological Science, University of Melbourne, Australia

OC10 - The Generation Program : Evaluating CNP520 Efficacy in Preclinical Alzheimer’s Disease
Cristina Lopez Lopez, MD, PhD1, Pierre N. Tariot, MD2, Angelika Caputo, PhD1, Fonda Liu, Pharm.D1, Marie-Emmanuelle Riviere, PhD1, Marie-Laure Rouzade-Dominguez, PhD1, Ronald G. Thomas, PhD1, Jessica B. Langbaum, PhD2, Rob Lenz, MD, PhD1, Eric M. Reiman, MD, PhD1, Ana Graf, MD1.

(1) Novartis Pharma, Basel, Switzerland; (2) University of California-San Diego, San Diego, CA, USA; (3) Amgen, Thousand Oaks, CA, USA.

CTAD 2017 Statistical Workshop : Estimands and Primary Analyses in AD Clinical Trials
Moderator : Hong Liu-Seifert Ph.D.
Eli Lilly and Company, Indianapolis, IN USA
Fabian Model Ph.D.
Roche, Basel Switzerland
Paul Aisen M.D.
Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA
Panel discussion

11:30 – 12:30 p.m.
Symposium 1
CTAD 2017 Statistical Workshop : Estimands and Primary Analyses in AD Clinical Trials
Moderator : Hong Liu-Seifert Ph.D.
Eli Lilly and Company, Indianapolis, IN USA
Fabian Model Ph.D.
Roche, Basel Switzerland
Paul Aisen M.D.
Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA
Panel discussion

12:30 – 1:30 p.m.
Lunch* (ABC Rooms) and Poster Session (Georgian Room)
*only for attendees who purchased the lunch package

1:30 – 2:30 p.m.
Oral Communications
Chairs: Samuel Henderson, Irwin H. Rosenberg

OC11 - A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 (abeotaxane) in Patients with Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy; or the Secondary Tauopathy, Alzheimer’s Disease.
Adam Boxer, MD, PhD1; Zachary Miller, MD1, Richard Tsai, MD, MBA1, Mary Koestler, RN, PhD1; Julio Rojas, MD, PhD1; Peter Lubenkov, MD1; Howie Rosen, MD1, Gil Rabinovic, MD1, Anne Fagan-Niven, PhD1; Yann Cobigo, PhD1, June Jung, PhD1; Phi Luong, BS1; Emmeline Chuu, BA1; Ryan Powers, BA1; Paige Mumford, BA1; Bruce Miller, MD1, Erin Roberson, MD1

(1) Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA; (2) Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA; (3) Department of Neurology, University of Alabama School of Medicine, Birmingham, AL, USA

OC12 - High dose B Vitamin therapy selectively improves cognitive function indicative of cerebrovascular status in the randomized FAVORIT Ancillary Cognitive Trial
Tammy M. Scott1,2, Aron M. Troen1,3, Irwin H. Rosenberg1,2

(1) Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston MA; (2) Friedman School of Nutrition Science and Policy, Tufts University, Boston MA; (3) Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel

OC13 - Investigational New Alzheimer’s Drug Tricaprilin: Results of a Phase 3 Study in Mild-to-Moderate Alzheimer’s Disease Patients
Samuel Henderson, PhD1, Michael Gold, MD2, Judith Walker, MD3, Sabrina Greer1, Janet Vogel1, Aaron Shenkin2

(1) Accera Inc, Boulder, CO, USA; (2) PPD Inc, Wilmington, NC, USA

OC14 - Characterization of the selective in vivo and in vitro binding properties of crenezumab: insights into crenezumab’s unique mechanism of action
William J. Meilandt1, Janice A. Maloney1, Jose Imperio1, Travis W. Bainbridge3, Mitse Reichelt1, Danielle Mandiliian1, Yannmei Lu3, James A. Ernst3, Reina N. Fujii3, Jasvinder K. Atwal1

(1) Department of Neuroscience, Genentech, South San Francisco, CA, USA; (2) Department of Protein Sciences, Genentech, South San Francisco, CA, USA; (3) Department of Research Pathology, Genentech, South San Francisco, CA, USA; (4) Department of Preclinical and Translational Pharmacology, Genentech, South San Francisco, CA, USA; (5) Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, CA, USA; (6) Department of Safety Assessment, Genentech, South San Francisco, CA, USA
Keynote 2
From Academy to Industry: Perspectives for Drug Trials in AD
Introduction: Michael Weiner, MD, University of California San Francisco (UCSF) USA
Rachelle Doody, MD, PhD
Global Head of Neurodegeneration PD Neuroscience, F. Hoffmann-La Roche, Basel, Switzerland

Late Breaking Oral Communications
Chairs: Virginia Pérez-Grijalba and Chin Hong Tan

LB5 - Targeting Tau with RO7105705: Phase I results and design of a Phase II study in prodromal-to-mild AD
Geoffrey A. Kerchner, MD, PhD; Gai Ayalon, PhD; Mira Blendstrup, MA; Flavia Brunstein, MD, PhD; Priya Chandra, PhD; Altash Datwani, PhD; Reina N. Fuji, VMD, PhD; Paul Manser, PhD; Rajesh Menon, MBA; Sandra Sanabria Bohorquez, PhD; Edmond Teng, MD, PhD; Michael Ward, PhD; Robby Weimer, PhD; Kristin R. Wildsmith, PhD; Corinne Foo-Akins, MBBS, MBA, MSc
Genentech, Inc, a member of the Roche Group, South San Francisco, CA, USA

LB6 - Plasma Aβ42/40 detects early stages of AD in the AB255 study and correlates with neuroimaging and CSF biomarkers.
Virginia Pérez-Grijalba, Judith Romero, Pedro Pesini, Leticia Sarasa, Itziar San-José, Javier Arbizu, Pablo Martínez-Lage, Lluís Tarragà, Àgustín Ruiz, Merçe Boada, Manuel Sarasa and The AB255 Araclon Group
(1)Araclon Biotech S.L., Zaragoza, Spain; (2)Clínica Universitaria de Pamplona, Pamplona, Spain; (3)Fundación CITA-Alzheimer, San Sebastián, Spain; (4)Alzheimer Research Center and Memory Clinic. Fundación ACE. Institut Català de Neurociències Aplicades. Barcelona, Spain

LB7 - Aducanumab 36-month data from prime: A randomized, double-blind, placebo controlled Phase IB study in patients with prodromal or mild Alzheimer’s disease
Samantha Budd Haeberlein, PhD; Sarah Gheuens, MD, PhD; Tianle Chen, PhD; John O’Gorman, PhD; Philipp von Rosenstiel MD; Ping Chiao, PhD; Guanfang Wang, PhD; Christian von Hehn, MD, PhD; LeAnne Skordos, PharmD; Christopher Hoch, MD; Roger M Nitsch, MD; Alfred Sandrock, MD, PhD
(1)Biogen, Cambridge, MA, USA (2) Cytel, Cambridge, MA, USA (3) Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

LB8 - Polygenic hazard score: an enrichment marker for Alzheimer’s associated amyloid and tau deposition
Chin Hong Tan, PhD; Chun Chieh Fan, MD; Elizabeth C. Mormino, PhD; Leo P. Sugrue, MD, PhD; Iris J. Brooke, PhD; Christopher P. Hess, MD, PhD; William P. Dillon, MD; Luite W. Bonham, BS; Jennifer S. Yokoyama, PhD; Celeste M. Karch, PhD; James B. Brewer, MD, PhD; Gil D. Rabinovici, MD; Bruce L. Miller, MD; Gerard D. Schellenberg, PhD; Karolina Kauppi, PhD; Howard A. Feldman, MD; Dominic Holland, PhD; Linda K. McEvoy, PhD; Bradley T. Hyman, MD, PhD; Ole A. Andreassen, MD, PhD; Anders M. Dale, PhD; and Rahul S. Desikan, MD, PhD for the Alzheimer’s Disease Neuroimaging Initiative
(1) Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA, USA (2) Department of Cognitive Science, UCSD, La Jolla, CA, USA (3) Department of Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA (4) Department of Neurology, UCSF, San Francisco, CA, USA (5) Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA (6) Department of Neurosciences, UCSD, La Jolla, CA, USA (7) Department of Radiology, UCSD, La Jolla, CA, USA (8) Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA (9) Department of Neurology, MGH, Boston, MA, USA (10) NOVUM Institute of Clinical Medicine, University of Oslo, Oslo, Norway

Coffee Break and Poster Session (Georgian Room)

Symposium 2
EPOCH Trial of the BACE1 Inhibitor Verubecestat for Mild-to-Moderate Alzheimer’s Disease
Presentation by Michael Egan MD, Merck & Co., Inc., Kenilworth, NJ, USA

Followed by Panel Discussion with
Paul Aisen MD, University of Southern California (USC), San Diego, CA, USA
Maria Carrillo PhD, The Alzheimer Association, Chicago, IL, USA
Jeffrey Cummings, MD, ScD, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
Bruno Vellas, MD, PhD University Hospital, Toulouse, France
Friday, November 3

08:30 – 10:00 a.m. Oral Communications

Chairs: Merce Boada and Bengt Winblad

**OC15** - Long-Term Cognitive Decline in Patients with Alzheimer’s Disease in Association with Treatment with Cholinesterase inhibitors-data from SveDem, the Swedish Dementia Registry

Maria Eritsdotter MD, PhD1,2, Sara Garcia-Ptacek MD, PhD1,2, Ingemar Kärehoti PhD1,2, Dorota Religa MD, PhD1,5, Peter Nordström MD, PhD6, Anders Wimo MD, PhD1,5, Bengt Winblad MD, PhD1,5

1,2 Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institute, Stockholm, Sweden; 1,5 Institute of Neurological Sciences, University of Glasgow, Glasgow, Scotland, UK; 2,5 Department of Neurobiology, Care Sciences and Society, Karolinska Institute Stockholm University, Stockholm, Sweden; 2,5 Institute of Gerontology, School of Health and Welfare, Jönköping University, Jönköping, Sweden; 2,5 Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division for Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden; 6 Department of Community Medicine and Rehabilitation, Karolinska University Hospital, Stockholm, Sweden; 7 The primary healthcare center of Hudiksvall-Nordanstig, Sweden

**OC16** - Selection of Amyloid Positive Pre-Symptomatic Subjects using Automatic Analysis of Neuropsychological and MRI Data for Cost-Effective inclusion Procedures in Clinical Trials

Manon Ansart, MSc1, Stéphane Epelbaum, MD, PhD2,3, Olivier Colliot, PhD2,3, Didier Dromont, MD2,3, Bruno Dubois, Prof., MD2,3, Harald Hampel, Prof., MD, PhD2,3,5, Stanley Durrleman, PhD2,1, for the ADNI, and the INSIGHT study group

1 Sorbonne Universités, UPMC Univ Paris 06, Inserm, CNRS, Institut du cerveau et la moelle (ICM); 2 Hôpital de la Pitié-Salpêtrière, Boulevards de l’Hôpital, Paris, France; 3 Inria Paris, Aramis project-team, Paris, France; 4 AP-HP, Hôpital de la Pitié-Salpêtrière, Department of Neurology, Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Paris, France; 5 AXA Research Fund & UPMC Chair, Paris, France

**OC17** - Physical Activity and Longitudinal Cognition: Results from the Harvard Aging Brain Study

Hannah M. Klein1, Dylan R. Kirn, MPH1, Aaron P. Schultz, PhD1, Jennifer S. Rabin, PhD1, Rachel Buchley, PhD2,3,5, Dorone M. Rentz, PsyD1,2, Kathryn V. Papp, PhD1,2, Keith A. Johnson, MD1,2, Reisa A. Sperling, MD MMSci1,2, Jasmeer P. Chhatwal, MD,PhD MMSci2,3

1 Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; 2 Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA; 3 Harvard Medical School, Boston, MA USA; 4 Department of Psychiatry, Massachusetts General Hospital, Boston, MA USA; 5 Florey Institutes of Neurosciences and Mental Health, Melbourne, Australia; 6 Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia

**OC18** - Validation of Tau PET Imaging in Alzheimer’s Disease and Other Tauopathies

Nítilas Mattsson, MD, PhD1,2, Michael Schöll MD, PhD1, Tomas Ollhson MD, PhD1, Andreas Hahn MD, PhD4, Olof Strandberg MD, PhD1, Jonas Jögi MD, PhD5, Ruben Smith MD, PhD6, Oskar Hansson MD, PhD1,2

1 Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden; 2 Memory Clinic, Ställe University Hospital, Malmö, Sweden; 3 Department of Radiation Physics, Ställe University Hospital, Lund, Sweden; 4 Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria; 5 Department of Clinical Physiology and Nuclear Medicine, Ställe University Hospital, Lund, Sweden; 6 Department of Neurology, Ställe University Hospital, Lund, Sweden

**OC19** - TOMMORROW: A Trial to Delay the Onset of MCI Due to AD and Qualify a Unique Genetic Algorithm Biomarker: Study Update

Kathleen A. Welsh-Bohmer, PhD1, Brenda L. Plassman, PhD2, Carl Chiang, PhD2, Meredith Culp, BSc1, Patrick Harrigan, BChE1, Janet O’Neil, MBA1, Ryan Walter, BSc1, Stephen Haneline, MSc1, Julian Arbucke, BSc [Hons]2, Shyama Brewster, BSc [Hons]2, Yukia Maruyama, D.V.M.1, Tom Swanson, BSCE, MBA1, Dominic Fitzsimmons, BSc [Hons]1, Alexandra S. Atkins, PhD1, Sarah Powell, MSN1, Richard Keefe, PhD1, Craig Mez, PhD1, Deborah Yarbrough, MS, MBA1, Daniel K. Burns, PhD1, Ann M. Saunders, PhD1, Robert Alexander, MD1 for the TOMMORROW study investigators

1 Department of Psychiatry & Neurology, Duke University, Durham NC, USA; 2 Zinfandel Pharmaceuticals, Inc, Chapel Hill NC, USA; 3 Takeda Development Center Americas, Inc, Deerfield, IL, USA; 4 NeuroCog Trials, Durham, NC, USA

**OC20** - Emerging Plasma-Based Therapies for AD

Montserrat Costa PhD1, Rael Burns, PhD1, Ana M Ortiz MSc1, Alba Pérez PhD1, Laura Núñez BSc2, Antonio Páez MD2, Mercé Boada MD1, Agustín Ruiz MD, PhD2, Salvador Grancha PhD1

1 Research & Development, Grifols Bioscience Industrial Group, Pareset del Vallès, Spain; 2 Clinical Operations Department: Grifols Bioscience Industrial Group, Sant Cugat del Vallès, Spain; 3 Memory Clinic of Fundació ACE: Institut Catàlau de Neurociències Aplicades, Barcelona, Spain

Coffee Break and Poster Session (Georgian Room)

10:30 – 11:00 a.m.

Keynote 3

Genetic Aspects In Clinical Trials

Introduction: Randall Bateman, MD - Washington University School of Medicine, St Louis, MO - USA

John Hardy, PhD - Reta Lila Weston Institute of Neurological Studies, University College London, London, UK
Friday, November 3

11:00 – 12:30 p.m.

**Oral Communications**

**Chairs:** Jessica B. Langbaum and Chengjie Xiong

**OC21 - Cognitive Run-In Periods for Amyloid-Positive Enriched Secondary Prevention Trials.**

Andrew J. Aschenbrenner¹, PhD, Jason Hassenstab², PhD, Eric McDade¹, DO, Guoqiao Wang³, PhD, Tammie L.S. Benzinger⁴, MD, PhD, Randall J. Bateman, MD, & John C. Morris, MD.

¹Department of Neurology, Washington University in St. Louis; ²Department of Psychological and Brain Sciences, Washington University in St. Louis; ³Department of Biostatistics, Washington University in St. Louis; ⁴Department of Radiology, Washington University in St. Louis.

**OC22 - Eigen Combinations of Cognition and Biomarkers to Minimize the Sample Sizes in Prevention Trials on Alzheimer Disease**

Chengjie Xiong¹,²,³,⁴, PhD, Anne M. Fagan¹,²,³, PhD, Tammie Benzinger¹,²,³,⁴, PhD, Jason Hassenstab¹,²,³,⁴, PhD, John C. Morris¹,²,³,⁴, MD, Randall J. Bateman¹,²,³,⁴, MD.

¹Department of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA; ²Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; ³Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; ⁴Department of Mathematics, Washington University, St. Louis, MO, USA; ⁵Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA; ⁶The Dominantly Inherited Alzheimer Network, Washington University School of Medicine, St. Louis, MO, USA

**OC23 - The Alzheimer’s Prevention Registry and GeneMatch: Accelerating Recruitment and Enrollment into Alzheimer’s Studies**

Jessica B. Langbaum, PhD¹, Nellie High¹, David Gordon¹, Jodie Nichols¹, Trisha Walsh¹, Eric M. Reiman¹, MD, Pierre N. Tariot¹, MD.

¹Banner Alzheimer’s Institute, Phoenix, AZ, USA

**OC24 - An Examination of Rate of Decline as an Alternative to Change from Baseline**

Howard Mactey, PhD¹, Nan Hu, PhD², Michael Ahmadi, MSc², Yinghua Chen, MSc², Pierre Tariot, MD³, Eric M Reiman, MD², Francisco Lopez, MD², Kewei Chen, PhD², Ronald Thomas, PhD².

¹Genentech, Inc, South San Francisco, CA, USA; ²Banner Alzheimer’s Institute, Phoenix, AZ, USA; ³Universidad de Antioquia, Medellín, Colombia; ⁴UC San Diego Department of Neurosciences, CA, USA

**OC25 - The Safety and Efficacy of Edonergic (T-817) in Patients with Mild to moderate Alzheimer’s Disease**

Lon S. Schneider, MD¹, Ronald G. Thomas, PhD², James Brewer, MD², Suzanne Hendrix, PhD², Robert Rissman, PhD², David Salmon, PhD², Hiroshi Kobayashi³, Howard Feldman, MD², for the ADCS TCAD group.

¹Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA; ²University of California, San Diego, CA, USA; ³Pentara Corporation, Salt Lake City, UT, USA; ⁴Toyama Chemical, Ltd, Tokyo, Japan

**OC26 - Safety of and Tolerability of Gantenerumab in the Open-Label Extension of SCarlet RoAD Trial, a Global Study in Patients with Prodromal Disease**

Mirjana Andjelkovic, PhD¹, Danielle Abi-Saab, Psy.D ¹, Nathalie Pross, PhD¹, Paul Delmar, PhD², Nicola Voyle, PhD², Michaela Mertes¹, Smiljana Ristic, MD¹.

¹Hoffman LaRoche, Basel, Switzerland; ²Roche Products Limited, Welwyn, UK

**Moderator:** Jeffrey Cummings, MD, ScD, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

1. **Role of 5-HT2a Receptors in the Pharmacology of Alzheimer’s disease Psychosis**

Stephen M. Stahl, MD, PhD¹, Ethan S. Burstein, PhD².

¹University of California, San Diego, CA, USA; ²ACADIA Pharmaceuticals Inc., San Diego, CA, USA

2. **Clinical Trial of Pimavanserin in Alzheimer’s disease Psychosis**

Clive Ballard, MBChB, MRCPsych¹, Carol Banister, MBChB, MRCPsych¹, Jim Youakim, MD³, Bruce Coate, MPH¹, Srdjan Stanitkovic, MD, MSPH³, on behalf of the ADP Investigators.

¹University of Exeter Medical School, Exeter, UK; ²King’s College, London, UK; ³ACADIA Pharmaceuticals Inc, San Diego, CA, USA

3. **Review of Pimavanserin Clinical Results in the Context of Historical Alzheimer’s disease Psychosis Trials**

Pierre N. Tariot, MD¹, Randall Owen, MD², Doral Fredericks, PharmD, MBA².

¹Banner Alzheimer’s Institute and University of Arizona College of Medicine, Phoenix, AZ, USA; ²ACADIA Pharmaceuticals Inc., San Diego, CA, USA

---

**Lunch** (ABC Rooms) *only for attendees who purchased the lunch package and Poster Session (Georgian Room and Ballroom Foyer)

12:30 – 1:30 p.m.

**1:30 – 2:30 p.m.**

**Symposium 3**

**Importance of Serotonin in Alzheimer’s Disease Psychosis and the Potential Role of Pimavanserin**

**Moderator:** Jeffrey Cummings, MD, ScD, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

**1. Role of 5-HT2a Receptors in the Pharmacology of Alzheimer’s disease Psychosis**

Stephen M. Stahl, MD, PhD¹, Ethan S. Burstein, PhD².

¹University of California, San Diego, CA, USA; ²ACADIA Pharmaceuticals Inc., San Diego, CA, USA

**2. Clinical Trial of Pimavanserin in Alzheimer’s disease Psychosis**

Clive Ballard, MBChB, MRCPsych¹, Carol Banister, MBChB, MRCPsych¹, Jim Youakim, MD³, Bruce Coate, MPH¹, Srdjan Stanitkovic, MD, MSPH³, on behalf of the ADP Investigators.

¹University of Exeter Medical School, Exeter, UK; ²King’s College, London, UK; ³ACADIA Pharmaceuticals Inc, San Diego, CA, USA

**3. Review of Pimavanserin Clinical Results in the Context of Historical Alzheimer’s disease Psychosis Trials**

Pierre N. Tariot, MD¹, Randall Owen, MD², Doral Fredericks, PharmD, MBA².

¹Banner Alzheimer’s Institute and University of Arizona College of Medicine, Phoenix, AZ, USA; ²ACADIA Pharmaceuticals Inc., San Diego, CA, USA
Late Breaking Oral Communications

Chairs: Peter J. Snyder and Christopher van Dyck

LB9 - Amylin type peptides as a new therapeutic avenue for Alzheimer’s disease

Wendy Qiu, M.D., Ph.D., Haihao Zhu, M.D., Ph.D., Robert A. Stern, Ph.D., Qishan Tao, Ph.D., Gustavo A. Mercier, M.D., Ph.D., Martin Farlow, M.D., Neil Kowall, M.D., Ph.D.

(1) Alzheimer’s Disease Center, (2) Department of Psychiatry, Boston University School of Medicine, Boston, MA, (3) Department of Pharmacology, Boston University School of Medicine (4) Department of Radiology, Boston University School of Medicine, Boston, MA, USA (5) Alzheimer’s Disease Center, Indiana University, Indianapolis, IN, USA

LB10 - Initial Experience with PET Imaging of Synaptic Density (5V2A) in Alzheimer’s Disease: A New Biomarker for Clinical Trials?

Ming-Kai Chen, MD, PhD, Adam P. Mecca, MD, PhD, Mika Naganawa, PhD, Sjoerd J. Finnema, PhD, Yukawa Toyonaga, PhD, Shu-fel Lin, PhD, Julia W. McDonald, Hannah R. Michaelak, Nabeel B. Nabulsi, PhD, Yiyun Huang, PhD, Amy F. T. Arnsen, PhD, Richard E. Carson, PhD, Christopher H. van Dyck, MD.

(1)Department of Radiology and Biomedical Imaging, Yale Positron Emission Tomography Center, Yale University, New Haven, CT, USA; (2)Department of Psychiatry, Yale University, New Haven, CT, USA; (3) Department of Neuroscience, Yale University, New Haven, CT, USA; (4)Department of Biomedical Engineering, Yale University, New Haven, CT, USA (5) Department of Radiology, Yale University, New Haven, CT, USA

LB11 - Early change in Retinal Structural Anatomy during the preclinical stage of Alzheimer’s disease

Peter J. Snyder, PhD, Claudia Y. Santos, MS, Jessica Alber, PhD, Lenworth N. Johnson, MD, Stuart Sinoff, MD, & Paul Maruff, PhD.

(1)Department of Neurology, Rhode Island Hospital & Alpert Medical School of Brown University, Providence, RI, USA (2) Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, RI, USA (3) Department of Ophthalmology, Rhode Island Hospital & Alpert Medical School of Brown University, Providence, RI, USA (4) Department of Neurology, BayCare Medical Group, Clearwater, FL, USA (5) Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (6) Cogstate Ltd, Melbourne, Victoria, Australia

LB12 - Online study partner-reported subjective cognitive decline can help identify potential Alzheimer’s clinical trial participants

Nosheny RL, Camacho M, Insel PS, Machin RS PhD, Finley S MS, Fennikhen D, Fochler J, Truran-Sacrey D, Maruff P, Weiner MW.

(1) Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran’s Administration Medical Center, San Francisco, CA (2) UCSF Department of Psychiatry, San Francisco, CA (3) UCSF Department of Radiology and Biomedical

Oral Communications

Chairs: Régis Bordet and Craig Ritchie

OC27 - The European Prevention of Alzheimer’s Dementia (EPAD) and Amyloid Imaging for Prevention of Alzheimer’s Dementia (AMYPAD) Projects: Cohort Readiness for the Adaptive Clinical Trial Platform.

Andrew Satlin, MD, Craig Ritchie MD PhD, Mila Kwiwietko MD PhD, Alina Soloman MD PhD, Brian Tom PhD, Jose Luis Molinuevo MD PhD, Scott Berry PhD, Frederik Barhof MD PhD, Gill Farrar PhD.

(1) Eisai Pharmaceuticals, USA (2) Centre for Dementia Prevention, University of Edinburgh, UK (3) Ageing Research Centre, Karolinska Institute, Sweden (4) MRC Biostatistics Unit, University of Cambridge, UK (5) Barcelona Brain Research Centre, Spain (6) Berry Consultants Ltd, Texas, USA (7) VU University Medical Centre, Amsterdam, The Netherlands (8) General Electric, Amersham, UK

OC28 - Towards a New Biomarker Battery for Drug Development in Alzheimer’s Disease

Olivier Blin, MD, PhD, Régis Bordet MD PhD, Jill Richardson PhD, Pierre Payoux MD PhD, Claudio Babiloni MD PhD, David Bartrés-Faz MD PhD, Catherine Cassé-Perot PhD, Giovanni Frisoni MD PhD.

(1) University of Aix-Marseille (2) University of Lille (3) CSK (4) University of Toulouse (5) University of Roma (6) University of Barcelona (7) University of Geneva

Coffee Break and Poster Session (Georgian Room and Ballroom Foyer)

Keynote 4

Rationale, Design and Progress of the 3 Active Alzheimer’s Prevention Initiative Trials

Introduction: Howard Feldman, MD, University of California at San Diego (UCSD) - USA

Pierre Tariot, MD, Banner Alzheimer’s Institute, University of Arizona College of Medicine, Phoenix, AZ - USA

Symposium 4

Results from the Phase 3 MINDSET STUDY: A Global, Double-Blind, Placebo-Controlled Study of Intepirdine in Mild-to-Moderate Alzheimer’s Disease
Saturday, November 4

08:30 – 10:00 a.m.

Oral Communications

Chairs: Audrey Gabelle, Zaven Khachaturian

OC29 - ORY-2001 Rationale in Mild to Moderate Alzheimer’s Disease
Roger Bulloch MD1, Cesar Molinero MD,PhD1, Tamara Maes PhD2
(1) Oryzon Genomics S.A, Barcelona Spain

OC30 - Plasma Amyloid Levels within the Alzheimer’s Process and Correlations with Central Biomarkers
Olivier Hanon, MD, PhD1, Jean-Sébastien Vidal MD, PhD1, Sylvain Lehmann MD, PhD2, Stéphanie Bombois MD, PhD3, Bernadette Alliquin MD4, Marie Godard Msc1, Patrick Gelé MD1, Christine Delmaire MD1, Frédéric Blanc MD4, PhD5, Schraen MD6, Audrey Gabelle MD, PhD7 and the BALTAZAR study group.
(1) Department of Gerontology, Broca Hospital, Paris, France ; (2) Laboratoire de Protéomique Clinique, Department of Biochemistry, Saint Eloi Hospital, RNRS, inserm ULBB, France ; (3) CERF de Lille, Department of Neurology, Lille, France ; (4) Centre de Psychiatrie et Neurosciences, Universite Paris Descarces, Paris, France ; (5) University of Lille Nord de France, Department of Biology and Pathology, Lille University Hospital, INSERM UMR 1172, 59037 Lille, France ; (6) CERF de Strasbourg, Department of Gerontology, Strasbourg, France ; (7) CERF de Montpellier, Department of Neurology, Inserm ULBB, Montpellier, France

OC31 - Online Clinical Research: Updates and Insights from the Brain Health Registry
Shannon Finley, MA1, Diana Truran1, Derek Flenniken1, Juliet Fochtler1, Rachel L. Nosheny PhD1, Monica Camacho1, R Scott Machin PhD1 and Michael W Weiner MD1,4
(1) Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran’s Administration Medical Center, San Francisco, CA, USA ; (2) UCSF Department of Psychiatry, San Francisco, CA, USA ; (3) UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA, USA

OC32 - BPNI4770 Phosphodiesterase-4D Negative Allosteric Modulator for Alzheimer’s Dementia: Preclinical, PET Imaging and Human Phase I Results
Mark Gurney, PhD1, Chong Zhang PhD2, Ying Xu PhD2, James O’Donnell PhD2, Masahiro Fujita MD, PhD1, Robert Innis MD, PhD2, Victor Pile PhD1, Sanjay Telu PhD1 and Scott Reines, MD, PhD1
(1) Tetra Discovery Partners, Inc. Grand Rapids, MI, USA ; (2) School of Pharmacy and Pharmacological Sciences, University at Buffalo, Buffalo, NY, US ; (3) National Institute of Mental Health, Bethesda, MD, USA

OC33 - Amyloid Beta Stable Isotope Labeling Kinetics and Concentrations of Human Plasma Detect CNS Amyloidosis
Vitaliy Ovod MS1, Kara Ramsey, BS1, James Bollinger PhD1, Vitaly Osipov, MS1, Maksim Palyanov, MS1, John Morris, MD1,2, Tammie Benzinger MD, PhD3,4, Anne Fagan PhD2,3,4, Bruce Patterson, PhD1, and Randall Baleman, MD1,2
(1) Department of Neurology, Washington University School of Medicine, St Louis, MO ; (2) Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO ; (3) Department of Radiology, Washington University School of Medicine, St Louis, MO ; (4) Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St Louis, MO ; (5) Department of Medicine, Washington University School of Medicine, St Louis, MO

OC34 - Stereotypical Data-Driven Imaging Biomarker Trajectories across the Alzheimer’s Disease Spectrum
Sergey Shcherbinin, PhD1, Mark A. Mintun, MD2, Adam J. Schwarz, PhD1, For the Alzheimer’s Disease Neuroimaging Initiative2
(1) Eli Lilly and Company, Indianapolis, IN, USA ; (2) Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA ; Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu)

10:00 – 10:30 a.m.

Coffee Break and Poster Session (Georgian Room and Ballroom Foyer)

10:30 – 11:30 a.m.

Late Breaking Oral Communications

Chairs: Michael Grundman and Philipp von Rosenstiel

LB13 - The Anti-Aβ Oligomer Drug CT1812 for Alzheimer’s: Phase Ib/2a Safety Trial Outcomes
Lon S Schneider, MD1, Michael Grundman, MD, MPH2, MS, Steven DeKosby, MD1,4, Roger Morgan, MD1,4, Robert Guttendorf5, Michelle Higgin, PhD1, Julie Pribyl1, Kelsie Mozison2, Nicholas J Izzo, PhD1, Hank Safferstein, PhD1, Celine Houser, RN1, Michael Woodward, MD, PhD Susan M. Catalano, PhD1
(1) Keck School of Medicine of USC, Los Angeles, CA, USA (2) Global R&D Partners, LLC, San Diego, CA, USA (3) Cognition Therapeutics, Inc., Pittsburgh, PA, USA (4) McKnight Brain Institute, University of Florida, Gainesville, FL, USA (5) MedSurfH2, LLC, Raleigh, NC, USA (6) Aclairo Pharmaceutical Development Group, Inc, Vienna, VA, USA (7) PharmaDLOCKS, Cary, NC, USA (8) Memory and Wound Clinics, Austin Health, Melbourne, Australia

LB 14 - “Proxy Antigens”: A new, definitive tool to guide successful clinical trials
Reddy Moeda, PhD1, Ronald N. Zucherman, PhD2, William Shelander, MSE3
(1) Arven Aalx Inc, Berkeley, California, USA. (2) Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, California, USA
LB15 - Value of 18F-florbetaben amyloid PET in the diagnostic work-up of most complex patients with dementia in France: a naturalistic study
Mathieu Ceccaldi, MD, PhD; Thérèse Jonveaux, MD; Antoine Verger, MD, PhD; Pierre Krolak-Salmon, MD, PhD; Claire Houzard, MD; Olivier Godefroy, MD; Trevor Shields, MD; Audrey Perrotin, PhD; Rossella Gismondi, MD; Santiago Bullich, PhD; Alecsandar Jovaletic, PhD; Nicola Raffa, MSIO; Florence Pasquier, MD; Franch Semah, MD; Bruno Dubois, MD; Marie Odile Habert, MD; David Wallon, MD; Mathieu Chastain, MD; Pierre Payoux, MD; Philip Alzheimer’s Disease; and NEUUS in AD study group; Andrew Stephens, MD, PhD; Eric Guedj, MD, PhD.

(1) AP-HM - Hôpital de la Timone, Neurology and Neuropsychology Department, and Aix Marseille University, Inserm, INS, Institute of Neurosciences des Systèmes, Marseille, France; (2) CHRU de Nancy – Hôpital Brabois, Centricat Department, Vandoeuvre-les-Nancy, France; (3) INSERM U578, IAD Nancy, France; (4) Clinical and Research Memory Center of Lyon, Hospices civils de Lyon, UCBL, INSERM U928, Lyon, France; (5) CHU Lyon, Nuclear Medicine Department, Lyon, France; (6) CHU Amiens Picardie - Hôpital Sud, Neurology Department, Amiens, France; (7) CHU Amiens Picardie - Hôpital Sud, Nuclear Medicine Department, Amiens, France; (8) Piramal Imaging, Medical Affairs, Berlin, Germany; (9) Piramal Imaging, Clinical Research and Development, Berlin, Germany; (10) Piramal Imaging, Market Access and HEOR, Berlin, Germany; (11) Inserm U77, Université de Lille, CHU DistAlz, Lille, France; (12) Univ. Lille, U177, CHU Lille, Nuclear Medicine Department, Lille, France; (13) AP-HP - Hôpital Pitié Salpêtrière, Memory and Alzheimer Disease Institute INCA, Paris, France; (14) Laboratoire d’Imagerie Biomédicale, Sorbonne Universités, UPMC, Univ Paris Inserm U 1166, CNRS UMR 7371, Paris, France; (15) CHU de Rouen - Hôpital Charles Nicolle, Neurology Department, Rouen, France; (16) Centre Henri Beaucquier Nuclear Medicine Department, Rouen, France; (17) ToNIC, Toulouse Neuroimaging Center, Université de Toulouse, Inserm, UPS, France; (18) AP-HP – Hôpital de la Timone, Nuclear Medicine Department, and Aix-Marseille University, ERINMED, CNRS, INT, Institut de Neurosciences de la Timone, Marseille, France.

LB16 - ADUCANUMAB titration dosing regimen: 24-month analysis from prime, a randomized, double-blind, placebo-controlled Phase IB study in patients with prodromal or Mild Alzheimer’s disease
Philipp von Rosenstiel MD; Sarah Gheuens, MD, PhD; Tianle Chen, PhD; John O’Gorman, PhD; Ping Chiao, PhD; Guaifeng Wang, PhD; Christian von Hehn, MD, PhD; LeAnne Skordos PharmD; Christoph Hock, MD; Roger M Nitsch, MD; Samantha Budd Haebnerlein, PhD; Alfred Sandrock, MD, PhD.

(1)Biogen, Cambridge, MA, USA (2)Cytel, Cambridge, MA, USA (3)Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

Symposium 5

Synaptic and Network Dysfunction in Alzheimer’s Disease (AD): Translational Insights and Therapeutic Opportunities
Moderator: Arjen Brussaard, PhD, Amsterdam Neuroscience, VU Medical Center, Amsterdam, Netherlands

1. Targeting unfolded protein response and synaptic dysfunction to enhance memory function and prevent neurodegeneration
Giovanna Mallucci, MD PhD
(1) Dept. of Clinical Neurosciences, University of Cambridge, Cambridge, UK; (2) UK Dementia Research Institute at University of Cambridge, Cambridge, UK; (3) MRI Toxicology Unit, Leicester, UK

2. Modulation of synaptic and network activity and endocytosis with light flicker therapy reduces amyloid pathology in mouse model of AD
Li-Hueh Tsai, PhD
(1) Picower Institute of Memory and Learning, Massachusetts Institute of Technology, Cambridge MA, USA

3. Preclinical rationale and early clinical results of p38 alpha kinase inhibition to reverse hippocampal synaptic dysfunction
John Alam, MD
(1) EIP Pharma, LLC, Cambridge MA, USA

Lunch* (ABC Rooms) *only for attendees who purchased the lunch package and Poster Session (Georgian Room and Ballroom Foyer)
Clinical Trials Prescreening Focus Panel: Prescreening Initiatives to Identify Individuals with Preclinical or Early Alzheimer’s Disease for Clinical Trials

Moderator: Jamie A Mullen, MD, AstraZeneca, Waltham MA, USA

1. The Funnel study: Prescreening for MCI and mild AD patients from the CHARIOT Register
   Neuroepidemiology and Ageing Research Unit, School of Public Health, Imperial College London, UK

2. A prescreening study using amyloid PET to improve recruitment for early Alzheimer’s disease drug trials
   Christopher C Rowe, MD Austin Health, Melbourne, Australia

3. Models of Patient Engagement in Alzheimer’s Disease (MOPEAD): a European project to move Alzheimer’s disease environment towards an earlier diagnosis
   Mercè Boada, MD, PhD1; Laura Campo2; Dhaval Desai3; Hans Peter Hundermann4; Octavio Rodriguez-Gomez, MD; Bengt Winblad, Prof, MD, PhD5; Franti Jessen, MD, PhD5; Peter Jelle Visser, MD, PhD5; Milica Kramberger, MD, PhD6; Rafael Navajo7; Annette Dumas8; Jean Georges, BA9; David Krivec10; Peggy Maguire11; Derek MacKenzie8
   (1) Fundació ACE. Barcelona Alzheimer Treatment & Research Center, Barcelona, Spain; (2) Eli Lilly and Company Ltd, Basingstoke, United Kingdom; (3) AstraZeneca AB, Sodermal, Sweden; (4) Lilly Deutschland GmbH, Bad Homburg, Germany; (5) Karolinska Institute, Center for Alzheimer Research, Div. of Neurogeriatrics, Huddinge, Sweden; (6) German Center for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany; (7) Zichting VLMC, Amsterdam, Netherlands; (8) University Medical Centre Ljubljana, Ljubljana, Slovenia; (9) Institut de I’Recerca Hospital Universitari Vall d’Hebron (IHRH), Barcelona, Spain; (10) CMV Soluciones Globales Internet S.A.U, Barcelona, Spain; (11) ASMD Consulting, Anderghem, Belgium; (12) Alzheimer Europe, Luxembourg, Luxembourg; (13) Spominica – Alzheimer Slovenia, Ljubljana, Slovenia; (14) European Institute of Women’s Health, Dublin, Ireland; (15) KITE Innovation (Europe) Ltd, Huddersfield, United Kingdom

Oral Communications

Chairs: Matthieu Ceccaldi and Curtis Tatsuoka

   Jason Hassenstab, PhD1,2,3,4, Andrew J. Aschenbrenner, PhD1,2,3,4, Eric McDade, DO1,2,3,4, Yen Ying Lim, PhD1,2,3,4, Paul Maruff, PhD1,2,3,4, David A. Balota, PhD1,2,3,4, John C. Morris, MD1,2,3,4, Randall J. Bateman, MD1,2,3,4, & The Dominantly Inherited Alzheimer Network-Trials Unit.
   (1) Department of Neurology, Washington University School of Medicine, St. Louis, MO USA; (2) Department of Psychological & Brian Sciences, Washington University in St Louis, St. Louis, MO USA; (3) The Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU); Washington University School of Medicine, St. Louis, MO USA; (4) Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO USA; (5) Department of Human Development and Family Studies, Pennsylvania State University, State College, PA USA; (6) The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia; (7) Cogstate Ltd, Melbourne, Victoria, Australia

OC36 - Associating Cognitive Functioning Profiles with Amyloid Status in ADNI2, with Implications for Adaptive Screening for Amyloid
   Sarah J Carr PhD1, Judith Jaeger PhD2,3, Nancy Maserejian ScD4, Ahmed Enayatallah*, Alan Lerner*, Yanming Wangó, Sheng Yang, Wenting Wang, Shijia Biang, Curtis Tatsuoka PhD** and for the Alzheimer’s Disease Neuroimaging Initiative*
   (1) Department of Neurology, Case Western Reserve University, Cleveland, OH, USA; (2) Cognimetrics, DE USA; (3) Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY USA; (4) Biogen, Cambridge, MA, USA; (5) Neurological Institute, University Hospitals Case Medical Center, Beachwood, OH, USA; (6) Department of Radiology, Case Western Reserve University, Cleveland, OH USA; (7) Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH USA

OC37 - Alzheimer’s Disease Dementia and the Long-Term Impact on Caregiver Burden – 36-Month results from GERAS
   Catherine Reed, PhD1, Mark Belger, BSc2, J. Scott Andrews, PharmD2, Antje Tochhorn-Heidenreich, MSc2
   (1) Eli Lilly and Company Limited, Windlesham, UK; (2) Eli Lilly and Company, Indianapolis, IN USA

OC38 - Neuroprotective Effect of a New Photobiomodulation Technique against Amyloid Aβ25-35 Peptide-Induced Toxicity in Mice.
   Guillaume J. Blivet, MS1, Johann Meunier, PhD2, Francois J. Roman, PhD2, Jacques Touchon, MD, PhD2
   (1) REGEN.JFE SAS, Montpellier, France; (2) Amylgen SAS, Montfernier-sur-Lez, France; (3) INSERM U1061, Montpellier, France; (4) University of Montpellier, France
Late Breaking Oral Communications

Chairs: Asa Hatami and Sharon Sha

**LB17 - Differential inhibition of the α-secretase ADAM10 by Aβ40 variants containing FAD mutations**
Asa Hatami1, Subrata Dutta2, Alejandro Rodriguez2, Patricia Spilman1, Jevgenij Rastatov2, Charles Glabe3, and Varghese John1
(1) Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles (2) Department of Chemistry and Biochemistry, University of California, Santa Cruz (3) Department of Molecular Biology and Biochemistry, University of California, Irvine

**LB18 - Clinical Pharmacokinetics and Pharmacodynamics Characterization of ANAVEX™-2-73 for Designing a Phase 2/3 Study in Mild-to-Moderate Alzheimer’s Disease**
Mohammad Afshar, MD, PhD1, Frédéric Parmentier, PhD1, Ene I Ette, PhD2, Emmanuel O Fadiran, PhD3, Christopher U Missling, PhD4; (1) Ariana Pharma, Paris, France, (2) Anoixis Corp., Natick, MA, (3) Anavex Life Sciences Corp., New York, NY

**LB19 - The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study**
Sharon J. Sha, MD, MS1, Gayle K. Deutsch, PhD1, Lu Tian, ScD, MS2, Kara Richardson3, Maria Coburn4, Jennifer Guadiosol, Tatiana Marcal5, Ethan Solomon, MS3, Athanasia Boumis1, Anthony Bet1, Steven P. Braithwaite, PhD2, Sam Jackson, MD, MBA3, Karoly Nikolich, PhD6, Darby Stephens5, Geoffrey A. Kerchner, MD, PhD, Tony Wyss-Coray, PhD7; (1) Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA (2) Department of Health Research and Policy, Stanford University, Stanford, CA, USA (3) Department of Neurosurgery, Stanford University, Stanford, CA, USA (4) Department of Pediatrics, Stanford University, Stanford, CA, USA (5) Endocrinology (current address) (6) Alzheimer’s Therapeutic Research Institute, University of Southern California, Los Angeles, CA, USA (current address) (7) Alithes, San Carlos CA, USA

**LB20 - Application of the revised diagnostic criteria for the early stages of Alzheimer’s disease to the LipiDiDiet study population**
Tobias Hartmann, PhD1,2, Kaj Blennow, PhD3,4, Pieter Jelle Visser, PhD5,6, Alina Solomon, MD, PhD7,8, Suzanne B Hendrix, PhD10, Miia Kivipelto, MD, PhD7,8,9, Hilkka Soiminen, MD, PhD7,8,9, Suzanne Hendrix, PhD10 on behalf of the LipiDiDiet clinical study group; (1) Deutsches Institut für Demenz Prävention (DIDP), Medical Faculty, Saarland University, Homburg, Germany (2) Department of Experimental Neurology, Saarland University, Homburg, Germany (3) Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiolog, Sahlgrensa University Hospital, Gothenburg, Sweden (4) Clinical Neurochemistry Laboratory, Sahlgrensa University Hospital, Malmö, Sweden (5) Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, Maastricht, the Netherlands (6) Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands (7) Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland (8) Department of Clinical Geriatrics, NVS, Karolinska Institutet, Huddinge, Sweden (9) Clinical Trials Unit, Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden (10) Pentara Corporation, Salt Lake City, UT, USA (11) Neurocenter, Department of Neurology, Kuopio University Hospital, Kuopio, Finland
Wednesday, November 1 and Thursday, November 2:
All posters presentations will be in Georgian Room (Mezzanine Level)

- **Theme 1. Clinical trials: Methodology**
  
P1 to P25 and LBPI to LBPI2 
  pages 20 - 23

- **Theme 2. Clinical trials: Results**
  
P26 to P42 and LBPI5 to LBPI32 
  pages 24 - 26

- **Theme 11. New therapies and clinical trials**
  
P114 to P129 and LBPI5 to LBPI24 
  pages 27 - 29

Friday, November 3 and Saturday, November 4
All posters presentations will be in Georgian Room and Ballroom Foyer (Mezzanine Level)

- **Theme 3. Clinical trials: Imaging**
  
P43 to P55 and LBPI35 to LBPI38 
  pages 30 - 31

- **Theme 4. Clinical trials: Biomarkers including plasma**
  
P76 to P77 and LBPI39 to LBPI46 
  pages 32 - 35

- **Theme 5. Clinical trials: Cognitive and functional endpoints**
  
P78 to P86 and LBPI47 to LBPI49 
  pages 36 - 37

- **Theme 6. Cognitive assessment and clinical trials**
  
P87 to P92 and LBPI50 to LBPI59 
  pages 37 - 38

- **Theme 7. Behavioral disorders and clinical trials**
  
P93 to P96 and LBPI60 to LBPI62 
  page 39

- **Theme 8. Health economics and clinical trials**
  
P97 to P99 and LBPI63 to LBPI64 
  page 40

- **Theme 9. Epidemiology and clinical trials**
  
P100 to P108 
  pages 40 - 41

- **Theme 10. Clinical Trials: Animal Models**
  
P109 to P113 and LBPI13 to LBPI14 
  page 42
Wednesday, November 1 and Thursday, November 2

Theme 1. Clinical trials : Methodology

P1: Japanese ADNI: Clinical, neuroimaging and biomarker profiles in comparison with ADNI
Takeshi Iwatsubo, MD1, Atsushi Iwata, MD1, Kazushi Suzuki, MD1, Ryoko Ibara, MD2, Hiroyuki Arai, MD2, Kenji Ishii, MD3, Michio Senda, MD4, Kengo Ito, MD1, Takeshi Ilheuchi, MD1, Ryozo Kuwano, MD5, Hiroshi Matsuda, MD5, for the Japanese ADNI and Chung-Kai Sun6, PhD, Laurel Beckett PhD6, Paul Aisen, MD8, Michael Donohue, PhD8, for the ADNI
(1) The University of Tokyo, Tokyo, Japan (2) Tohoku University, Sendai, Japan (3) Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan (4) Institute of Biomedical Research and Innovation, Kobe, Japan (5) National Center for Geriatrics and Gerontology, Obu, Japan (6) Niigata University, Niigata, Japan (7) National Center for Neurology and Psychiatry, Kodaira, Japan (8) Alzheimer Therapeutics Research Institute, University of Southern California, San Diego, CA, USA (9) University of California, Davis, Sacramento, CA, USA

P2: Putting the PGSA to the test: Time to progression in five studies with MCI patients
Manfred Berres, PhD, RheinAhrCampus, Remagen, Germany; Andreas U. Monsch, PhD, Memory Clinic, University Center for Medicine of Aging, Felix Platter Hospital, Basel, Switzerland and Rene Spiegel, PhD, University Center for Medicine of Aging, Felix Platter Hospital, Basel, Switzerland.

P3: The importance of correct specification of the within-subject correlation structure in sample size calculation and power analysis for an AD clinical trial utilizing mixed effects regression analysis for outcome assessment
Wenyaw Chan, Ph.D1., Ho-Lan Peng, Ph.D1, Valory N. Pavlik, Ph.D.2
(1) Department of Biostatistics, University of Texas Health Science Center at Houston, Houston, Texas, USA (2)Department of Neurology, Baylor College of Medicine, Houston, Texas, USA

P4: Join Dementia Research Improving Delivery of Clinical Trials in the UK
Adam Smith
Office of the NIHR National Director for Dementia Research, University College London, UK

P5: Evaluation of Rapid, on-Site APOE Genetic Testing for Subject Outreach and Trial Recruitment
Sharon Cohen, MD FRCP, Stephen G. Thein, PhD2, Ian Cohen, MD CCFP1, Sophia Marie Pogralghan, MD1, Fadi Frankhi, MBChB1
(1) Toronto Memory Program, Toronto, ON, Canada (2) Pacific Research Network, San Diego, CA, USA

P6: Implementing a Memory Clinic Model to facilitate recruitment into early phase clinical trials for Mild Cognitive Impairment and Alzheimer’s Disease
Lovingly Part, Ph.D1, Lev Gertsitl, MD2, Zanya Mendoza, PsyD.2, Katrina Patrich, Ph.D.2, Darlene Gullabal, Airybel Rodrigez2, and Stanford Jhee, PharmD
(1)PAREXEL International, Glendale, CA (2) California Clinical Trials Medical Group, Glendale, CA, USA

P7: AD clinical trial recruitment Capacity to screen delivers faster recruitment
Roger Bulloch, MD1 Mette G. Shahsen 2 Susanne B. Olesen 2 Aina S. Lihn, MD, PhD 2
Ulla Schmidt, MD1 Hans Chr. Hoech MD, PhD 1
Bioclinica Research Network, Stans NW, Switzerland; (2) Bioclinica Research Network, Aalborg, Denmark; (3) Bioclinica Research Network, Vejle, Denmark; (4) Bioclinica Research Network, Ballerup, Denmark

P8: Clinical and psycsmatic characteristics of participants with preclinical Alzheimer’s disease in Japanese ADNI
Ryoko Ihara, MD1, Atsushi Iwata, MD1, Kazushi Suzuki, MD1, Takeshi Iwatsubo, MD1, Hiroyuki Arai, MD2, Kenji Ishii, MD3, Michio Senda, MD4, Kengo Ito, MD5, Takeshi Ilheuchi, MD5, Ryozo Kuwano, MD6, Hiroshi Matsuda, MD7 for the Japanese ADNI
(1) The University of Tokyo, Tokyo, Japan (2) Tohoku University, Sendai, Japan (3) Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan (4) Institute of Biomedical Research and Innovation, Kobe, Japan (5) National Center for Geriatrics and Gerontology, Obu, Japan (6) Niigata University, Niigata, Japan (7) National Center for Neurology and Psychiatry, Kodaira, Japan

P9: A novel mixed effects model to simultaneously estimate how the baseline value and the longitudinal change in biomarkers predict the change in cognition in dominantly inherited Alzheimer's disease
Guoqiao Wang, PhD1, Chengjie Xiong, PhD, Eric M. McCade, DO1, Jason Hassenshab, PhD1, Anne M. Fagan, PhD1, Tammie L.S. Benzinger, PhD, John C. Morris, MD1, Andrew J. Aschenbrenner, PhD, Randall J. Bateman, MD1
The Dominantly Inherited Alzheimer Network, Department of Neurology, Washington University School of Medicine, St. Louis, MO
Wednesday, November 1 and Thursday, November 2

P10: An examination of rate of decline as an alternative to change from baseline
Howard Mackey, PhD1, Nan Hu, PhD1, Michael Malek-Ahmadi, MSc2, Yinghua Chen, MSc2, Pierre Tariot, MD2, Eric M Reiman, MD2, Francisco Lopera, MD1, Kewei Chen, PhD1, Ronald Thomas, PhD1
(1) Genentech, Inc., South San Francisco, CA, USA. (2) Banner Alzheimer’s Institute, Phoenix, AZ, USA. (3) Universidad de Antioquia, Medellin, Colombia. (4) UC San Diego Department of Neurosciences, CA, USA.

P11: Metric Collection for Research Site Optimization: Global Alzheimer’s platform efforts toward creating an AD research site database.
Richard Mohs, PhD1, Kate Zhong, MD1, John Dwyer, JD1, Jason Borh, MA1, Gabe Goldfeder, MA1
Global Alzheimer’s Platform, Washington, D.C., USA.

P12: In vitro degradation of β-amyloid fibrils by microbial keratinases
Debananda Singh Ningthoujam, DBT-State Biotech Hub (SBT Hub) & Microbial Biotechnology Research Laboratory (MBRL), Manipur University, Canchipur, Imphal, India.

P13: A likelihood-based prediction of Alzheimer’s dementia using biomarkers: applications for clinical trials
Igor Yakushev, MD1, Felix Müller-Sarnowshi, MD1, Bing Si, PhD1, Jing Li, PhD1, Timo Grimmer, MD2
(1) Dept. of Nuclear Medicine, Technical University of Munich. (2) Dept. of Psychiatry and Psychotherapy, Technical University of Munich. (3) Dept. of Industrial Engineering, Arizona State University.

P14: A randomized placebo-controlled cross-over trial investigating nabilone as a treatment for agitation in patients with advanced AD: study protocol
Myuri Ruthirakuhan, PhD1,2,3, Nathan Herrmann, MD, FRCPC1,2,3, Eleener H. Abraham, BSc1,2, Chelsea Sherman, BSc1,2,3, Nicolaas Paul L.G. Verhoeff, MD, FRCPC, PhD1,2, Alex Köss, PhD1, Sandra E. Black, MD, FRCPC1,2, Ana C. Andreazza, PhD1 and Krista L. Lanctot, PhD1,2,3
(1) Sunnybrook Research Institute, Toronto, ON, Canada. (2) University of Toronto, Toronto, ON, Canada. (3) Neuropsychopharmacology Research Group, Toronto, ON, Canada. (4) Baycrest Health Sciences, Toronto, ON, Canada.

P15: Enriching Clinical Trial Data through Co-enrollment with the Brain Health Registry
Juliet Fockler1,2, Rachel L. Nosheeny PhD1,2, Diana Truran, Shannon Finley, MA1, Monica Camacho1, Derek Fennelten1, Aaron Ulbricht1, R Scott Machin PhD1,2, Gil Rabinovici MD1,2, and Michael W Weiner MD1,2
(1) Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran’s Administration Medical Center, San Francisco, CA, USA. (2) UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA, USA. (3) UCSF Department of Psychiatry, San Francisco, CA, USA. (4) UCSF Department of Neurology, San Francisco, CA, USA.

P16: Outcomes and Length of Pharmacotherapy Trials on Alzheimer’s disease
Enea Traini, PhD1, Michele Moruzzi, PhD1, Francesco Amenta, MD1
Centre for Clinical Research, Telemedicine and Telepharmacy, University of Camerino, Camerino.

P17: Electrophysiology of the GABA and Cholinergic systems in healthy elderly subjects
Kristinn Johnsen, PhD1, Peter Draxler, PhD, Gísli Johannesson, PhD1, Magnus Johannsson, MSc1, Thorhild Gudmundsson, MD1, Jon Snaedal, MD2
(1) Research and Development, MentisCura, Reykjavíkt, Iceland. (2) Geriatrics, Landspitali University Hospital, Reykjavíkt, Iceland.

Christopher Weber, PhD1, Selam Negash, PhD1, Michael Ropachi, PhD1, Michael Randolph, PhD12
(1) MedAvant, Inc. (2) Loyola University Medical Center.

P19: Study design and protocol of the Nolan trial: A randomized controlled trial of a nutritional blend to prevent cognitive decline in older adults
Claudie Hooper, PhD1, Sophie Guyonnet, PhD1, Corina Boschat PhD1, Julie Hudry PhD1, Sandrine Andrieu MD, PhD2,3, Jeronen Schmitt PhD1,2, Bruno Vellas MD, PhD1
(1) Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France. (2) UMRIO27, Université de Toulouse, UPS, INSERM, Toulouse, France. (3) Nestlé Research Center, Vers-chez-les-Blanc, Switzerland. (4) Department of Epidemiology and Public Health, CHU Toulouse, Toulouse, France. (5) Center of Human Psychopharmacology, Swinburn University of Technology, Melbourne, Australia.
**Wednesday, November 1 and Thursday, November 2**

**P20: Validating Trial Power in Presence of Non-Random Dropouts Using Disease Simulation**  
Ali Tafazzoli, PhD¹, Peter L. Quon, MPH¹, Sean Stern, MS¹, Anuraag Kansal, PhD¹  
(¹Evidera, Bethesda, MD, USA)

**P21: Accounting for baseline prognostic variables and patient drop-out in the analysis of longitudinal outcomes within randomized trials for Alzheimer’s Disease.**  
Elizabeth Colantuoni, PhD¹; Michael Rosenblum, PhD¹; Jon Steingrimsson, PhD¹; Aidan McDermott, PhD¹; Arnold Bakter, PhD¹; Michela Gallagher, PhD²  
(¹Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA (2) Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medical School, Baltimore, MD USA (3) AgeneBio, Inc. Baltimore, MD USA (4) Department of Psychological and Brain Sciences, Johns Hopkins University, Baltimore, MD USA)

**P22: An open-source implementation of data standards for Alzheimer’s Disease clinical trials**  
Chung-Kai Sun, MS³; Michael Donohue, PhD¹; Karin Ernstrom, MS¹; Yanxin Jiang, MS¹; Zeyun Lu, MS¹; Paul Aisen, MD¹; Rema Raman PhD¹  
(¹Alzheimer Therapeutics Research Institute, University of Southern California, San Diego, CA, USA)

**P23: Longitudinal Impact of Audio Review on Data Quality**  
Todd M. Solomon, PhD², Jordan M. Barbone, BS³, Sarah M. Karas PsyD¹, H. Todd Feaster PsyD¹  
(¹Bracket, Wayne, PA, USA; ²Boston University School of Medicine, Boston, MA, USA)

**P24: Utilizing Audio Review to Improve ADCS-ADL Data Quality**  
Todd M. Solomon³, PhD; H. Todd Feaster PsyD¹; Jordan M. Barbone, BS³ and David S. Miller, MD, MA¹  
(¹Bracket, Wayne, PA, USA; ²Boston University School of Medicine, Boston, MA, USA)

**P25: The influence of a mobility training program on gait performance among healthy cognitive elderly people and people with MCI**  
Carine Federspiel, MD³, Elisabeth Bourkel, PhD¹, Jean-Paul Steinmetz, PhD¹  
(¹Centre for memory and mobility, Luxembourg; ²ZithaSenior, Research & Development, Luxembourg)

**Late Breaking Posters**

**LBP1: Now I Remember! (That I’m in Another Study): Duplicate Subjects in Clinical Trials of Alzheimer’s Disease**  
Thomas Shiovitz, MD¹,², Brittany Fox, BS¹, Chelsea Steinmetz, BA¹, Sabrina Schoneberg, BA¹  
(¹CTSdatabase LLC, Sherman Oaks, CA, USA ²California Neuroscience Research, Sherman Oaks, CA, USA)

**LBP2: Alzheimer’s Disease should we jump, sink or swim through phase 2? How do different early phase designs address Alzheimer’s issues?**  
Trevor Smart,  
Eli Lilly, Wiltshire, Surrey, United Kingdom

**LBP3: Low PET screen failure rate in the UB-311 Phase 2A study enriched for ApoE4 carriers with mild cognitive deficit**  
Hui Chen Chen¹, P. N. Wang², M. J. Chiu, MD³, C. C. Huang³, C. C. Chang³, T. C. Yen³, K. J. Lin³, John Seibyl⁴, Jacob Hesterman⁴, Ajay Vermal⁴  
(¹United Neuroscience, Inc. Hauppauge, NY, USA; ²Department of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan; ³Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan; ⁴Department of Neurology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; ⁵Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; ⁶Molecular Imaging Center and Department of Nuclear Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; ⁷InvICRO LLC, Boston, MA, USA)
**POSTER PRESENTATIONS**

**Wednesday, November 1 and Thursday, November 2**

**LBP4:** The Brain Health Registry-IDEAS study: Evaluating the feasibility of Internet-based data collection in cognitively impaired older adults

Monica R Camacho1,2, Rachel L Nosheny PhD1,2, Shannon Finley MA1, Derek Flenniken1,2, Juliet Fochler1, R Scott Machin PhD1,3, Diana Truran-Sacrey1, Aaron Ulbricht1,2, J Wesson Ashford1,5, Curtis B Ashford5, Gil Rabinovici MD1, James Hendrix6, Maria Carrillo6, and Michael W Weiner MD2

(i) Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran’s Administration Medical Center, San Francisco, CA, USA (2) UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA, USA (3) UCSF Department of Psychiatry, San Francisco, CA, USA (4) Stanford Department of Psychiatry & Behavioral Science, Palo Alto, CA, USA (5) Palo Alto Veteran’s Administration Medical Center, Palo Alto, CA, USA (6) MemTrax, Inc, Redwood City, CA, USA (7) UCSF Department of Neurology, San Francisco, CA, USA (8) Alzheimer’s Association, Chicago, IL, USA

**LBP5:** Frailty and biological ageing may impact the external validity of randomized controlled trials on Alzheimer’s disease.

Alessandro Trebbastoni1, Marco Canevelli1, Federica Quarata1, Fabrizia D’Antonio1, Matteo Cesari2, Giuseppe Bruno1 and Carlo de Lena1

(1) Department of Neurology and Psychiatry, “Sapienza” University of Rome, Italy (2) Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France (3) Université de Toulouse III Paul Sabatier, Toulouse, France

**LBP6:** Clinical trial design of the CREAD Studies: randomized, double-blind, placebo-controlled, parallel-group Phase 3 studies to evaluate the efficacy and safety of crenezumab in patients with prodromal to mild Alzheimer’s disease

Helen Lin, MD 1, Janice Smith, PhD2, Laurie Millar, PhD2, Kayceee M. Sink, MD, MAS2, Jillian Smith, BSc1, Andres Schneider, MD1, Reina Fuji, VMD, PhD1, Angelica Quintero, PhD3, Howard Machey, PhD3, Michael Rabbia, MA4, Susan Yule, B.Pharm4, Susanne Ostrowitzki, MD, PhD5, Paulo Fontoura, MD, PhD5, Rachel Doody, MD, PhD5

(1) Genentech, Inc., South San Francisco, USA; (2) Roche Products Ltd, Welwyn Garden City, UK (3) F. Hoffmann-La Roche Ltd, Basle, Switzerland (4) Roche Innovation Center New York, New York, NY

**LBP7:** Utilizing machine learning to enable improved cohort selection for Alzheimer’s Disease clinical trials

Mallory Busso BSc1, Emmanuel Fuentes BSc1, Christopher Buchley PhD2, Rabia Ahmad PhD2, Christopher Foley PhD2, Jan Wolber PhD2

(1) GE Healthcare, Life Sciences, San Ramon, USA (2) GE Healthcare, Life Sciences, Core Imaging, Amersham, UK

**LBP8:** Does the Length of Time to Clinical Trial Site Activation Relate to Screening Performance?

Sarah Walter, MSc1, Devon Gessert, BS1, Elizabeth Shaffer-Bacareza, BS1, Karin Ernstrom, MS1, Rema Raman, PhD1, Paul Aisen, MD1

(1) Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA

**LBP9:** Next Generation of Clinical Development: Applying Patient-Centered Insights to Accelerate Patient Recruitment for Alzheimer’s Disease Clinical Trials

Olga Usypenshaya-Cadoz, MD, PhD2, Kenneth Stanley2, Natalia Balto3, Sadiq Lula3, Sam Khinda3, Milena Kanova, MD3, Penny Randall, MD3, Lynne Hughes2

(1) QuintilesIMS Central Nervous System Center of Excellence (2) QuintilesIMS Project Leadership Unit (3) QuintilesIMS Analytics Center of Excellence

**LBP10:** Experimental Design on a Budget for Sparse Linear Models: Applications to Cognitive Patterns in Preclinical Alzheimer’s Disease

Daniel J. Belongia1, Sathya N. Ravi1, Rebecca Koscilt, PhD1, Erin Jonaitis, PhD1, Sterling C. Johnson, PhD1, Viktas Singh, PhD1

(1) University of Wisconsin – Madison (2) William S. Middleton Memorial Veterans Hospital

**LBP11:** Rationale, Design and Progress of Alzheimer's Prevention Initiative Trials

Pierre N. Tariot, MD1, Jessica B. Langbaum, PhD2, Eric M. Banner

Alzheimer’s Institute, Phoenix, AZ, USA

**LBP12:** Graph Imputation techniques for estimating amyloid positivity from longitudinal cognitive and MRI measurements for efficient secondary prevention trials

Tuan Dinh, Sathya Ravi, Won-Hwa Kim, Nagesh Adluru, Rebecca Koscilt, Cynthia Carlsson, Sterling C. Johnson, Viktas Singh

University of Wisconsin-Madison, WI, USA
Theme 2. Clinical trials: Results

P26: Longitudinal cognitive and functional changes are influenced by educational history in the J-ADNI MCI individuals.
Atsushi Iwata, MD1, Takeshi Iwatsubo2, MD, Kazushi Suzuki, MD1, Ryozo Ihara, MD1, Hiroyuki Arai, MD1, Kenji Ishii, MD1, Michio Senda, MD6, Kenzo Ito, MD4, Takeshi Ilieuchi, MD1, Ryozo Kuwano, MD1, Hiroshi Matsuda, MD4 for the Japanese ADNI
(1) Department of Neurology, The University of Tokyo, Tokyo, Japan (2) Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan (3) Department of Molecular Imaging, Institute of Biomedical Research and Innovation, Kobe, Japan (4) Department of Clinical and Experimental Neuroimaging, National Center for Geriatrics and Gerontology, Oiso, Japan (5) Brain Research Institute, Niigata University, Niigata, Japan (6) Integrative Brain Imaging Center, National Center for Neurology and Psychiatry, Kodaira, Japan

P27: A randomized placebo-controlled cross-over trial investigating nabilone as a treatment for agitation in patients with advanced AD: study protocol
Myuri Ruthirakan, PhD1,2,3, Nathan Herrmann, MD, FRCPC1,2,3, Eleonor H. Abraham, BSc1, Chelsea Sherman, BSc1,3, Nicolaas Paul L.G. Verhoef, MD, FRCP, PhD1,4, Alex Kiss, PhD1, Sandra E. Blach, MD, FRCP1, Ana C. Andreazza, PhD1 and Krista L. Lancot, PhD1,3
(1) Sunnybrook Research Institute, Toronto, ON, Canada (2) University of Toronto, Toronto, ON, Canada (3) Neuropsychopharmacology Research Group, Toronto, ON, Canada (4) Baycrest Health Sciences, Toronto, ON, Canada

P28: BPN14770 Phosphodiesterase-4D Negative Allosteric Modulator for Alzheimer’s Dementia: Preclinical, PET Imaging and Human Phase I Results
Mark Gurney, PhD1, Chong Zhang PhD2, Ying Xu PhD2, James O’Donnell PhD1, Masahiro Fujita MD, PhD2, Robert Innis MD, Phd3 and Scott Reines, MD, PhD1
(1) Tetra Discovery Partners, Inc. Grand Rapids, MI, USA (2) School of Pharmacy and Pharmacological Sciences, University at Buffalo, Buffalo, NY, US (3) National Institute of Mental Health, Bethesda, MD, USA

P29: Sustained Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Alzheimer’s Disease over 130 weeks: Results of Phase 3 Extension Study
S. Abushakra, MD1, A. Porsteinsson, MD2, C. SAdowsky, MD3, B. Vellas, MD4, S. Gauthier, MD5, A. Power, MD6, L. Shen, PHD7, P. Wang, PHD7, J.A. Hey, PHD1, M. Tolar, MD, PHD6
(1)Alzheon, Inc., Boston, MA, USA (2)University of Rochester, Rochester, NY (3)Palm Beach Neurology, Florida USA (4)University of Toulouse, Toulouse, France (5) McGill University, Montreal, Canada (6)Pharmacare Inc., San Diego, CA US

P30: Effect of mild or moderate hepatic impairment on the clearance of azeliragon
Ann Gooch, PhD1, Aaron H Burstein, PharmD1, Scott J Brantley, PhD1, Michael J Lamson, PhD1, Imogene Dunn, PhD1, Larry D Altsieli, MD, PhD1
(1) vTv Therapeutics, High Point, NC, USA (2) Nuventra Pharma Sciences, Inc, Durham, NC, USA

P31: Effect of CYP2C8 and CYP3A4 inhibition and CYP induction on the pharmacokinetics of azeliragon.
Aaron H Burstein, PharmD1, Michael J Lamson, PhD1, Mark Sale, MD, Scott J Brantley, PhD1, Ann Gooch, PhD1, Imogene Dunn, PhD1, Larry D Altsieli, MD, PhD1
(1) vTv Therapeutics, High Point, NC, USA (2) Nuventra Pharma Sciences, Inc, Durham, NC, USA

P32: The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
Sharon J. Sha, MD, MS1, Gayle K. Deutsch, PhD2, Lu Tian, ScD2,5, B. Vellas, MD2, Mara Coburn3, Jennifer Guadisolo, Tatiana Marcati4, Ethan Solomon, MS5, Athanasia Bounis1, Anthony Bent3, Steven P. Braithwaite, PhD4, Sam Jackson, MD, MBA5, Karoly Nikolich, PhD6, Darby Stephens6, Geoffrey A. Kerchner, MD, PhD1, Tony Wyss-Coray, PhD6
(1)Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA (2)Department of Health Research and Policy, Stanford University, Stanford, CA, USA (3)Department of Neurosurgery, Stanford University, Stanford, CA, USA (4) Department of Pediatrics, Stanford University, Stanford, CA, USA (5) Department of Endocrinology (current address) (6) Alzheimer’s Therapeutic Research Institute, University of Southern California, Los Angeles, CA, USA (current address) (7) Alkhest, San Carlos CA, USA

P33: FUNDAMANT: a 72-week phase I follow-up study of AADvac1, an active vaccine against tau pathology
Petr Novak, MD, PhD1, Matej Ondrus, MD, MSc1, Stanislav Katina, PaedDr. RNDr, Norbert Zilka, MVD, DrSc (Eva Kontsekova, RNDr, Prof, DrSc)
(1) AXON Neuroscience CRM Services SE, Bratislava, Slovakia (2) AXON Neuroscience R&D Services SE, Bratislava, Slovakia
P34: Open-Label Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer’s Disease
Lutz Frölich, MD,1 Jose Luis Molinuevo, MD,2 Alireza Atri, MD, PhD,3,4 Clive Ballard, MD,5 Neli Boneva, MD, PhD,6 Marie Aavang Geist, PhD,6, Anna Bladström, PhD,6 Jeffrey L. Cummings, MD, ScD,6 Pierre N. Tariot, MD,6 (1) Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany, (2) Alzheimer’s disease and other cognitive disorders unit, Neurology Service, ICN Hospital C. Inclán and Universitat Politecnica de Catalunya, Barcelona, Spain, (3) Ray Dolby Brain Health Center, California Pacific Medical Center, San Francisco, CA, USA, (4) Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA, (5) University of Exeter Medical School, Exeter, UK (6) H Lundbeck A/S, Valby, Denmark (7) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA (8) Banner Alzheimer’s Institute, Phoenix, AZ, USA

P35: A Ketogenic Supplement Improves Brain Energy Metabolism and Cognition in Mild Cognitive Impairment: Preliminary Results of a 6-Month Randomized Controlled Study with Neuroimaging (BENEFIC TRIAL)
Etienne Croteau, PhD,2 Christian-Alexandre Castellano, PhD,2 Melanie Fortier, MSc1 Francis Langlois, PhD1 Tamas Fulop, MD, PhD,1 Stephen Cunnane, PhD,2 (1) Research Center on Aging, CIUSSSSE – CHUS, Sherbrooke, QC, Canada (2) Pharmacology-Physiology department, FMSS, University of Sherbrooke, QC, Canada (3) Medicine department, FMSS, University of Sherbrooke, QC, Canada

P36: MRI findings in the open label extension of the Marguerite RoAD study in patients with mild Alzheimer’s disease
Danielle Abi-Saab, Psy.D,1 Mirijana Andjelkovic, PhD,1 Nathalie Pross, PhD,1 Paul Delmar, PhD,1 Nicola Voyle, PhD,1 Nelli Esau, Smiljana Ristic, M.D,1, (1) Hoffman LaRoche, Basel, Switzerland (2) Roche Products Limited, Welwyn, UK

P37: Three Years of Treatment of the Trial on the Association between a Cholinesterase Inhibitor and Choline Alphoscerate in Alzheimer’s Disease: Interim Results
Enea Traini, PhD,1 Anna Carotenuto, PhD,2, Angiola M Fasanaro, MD,2 Valentino Manzo, MD,2 Francesco Amenta, MD,2 (1)Centre for Clinical Research, Telemedicine and Telepharmacy, University of Camerino, Camerino, (2)Alzheimer Evaluation Unit, National Hospital, “A. Cardarelli”, Naples, Italy

P38: Safety and Efficacy Results from Phase 2 pilot trial of GM-CSF/Leutin® in mild-to-moderate AD
Huntington Potter, PhD,1 Jonathan H. Woodcock, MD,2 Timothy Boyd, PhD,2 Stefan H. Sillau, PhD,2 Brianne M. Betcher, PhD,2,3 Joseph Daniels,1, Kate Hefferman,1, and H. Gray2 (1) Rocky Mountain Alzheimer’s Disease Center, Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA (2) CNC Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO, USA (3) Department of Neurosurgery, University of Colorado School of Medicine, Aurora, CO, USA

P39: Analysis of treatment emergent adverse event incidences in phase 2 study of azeliragon reveal potential attenuation of psychiatric system organ class (SOC) adverse events and expected drug effects in gastrointestinal SOC
Imogene Dunn, PhD,1 Aaron H Burstein, PharmD,1 Larry D Altstiel, MD, PhD1 (1) VTV Therapeutics, High Point, NC, USA

P40: Treatment with PXT-864 showed stabilisation of cognitive disability in mild Alzheimer’s disease after 36 weeks
Jacques Touchon, MD PhD,1 Pierre-Jean Ousset, MD,2,3 Florence Pasquier, MD PhD,2 Claude Guériot, MD,2,3 Philippe Robert, MD, PhD,1 Sophie Auriacombe, MD,4,5 Jean-Marc Orgogozo, MD, PhD,5 Jacques Hugon, MD, PhD,5 Peter Schmit, PhD,5 Anne-Claire Coyne, PhD,5 Rodolphe Hajj, PhD,1 René Goedkoop, MD,1,4,5,6,7,8, René Goedkoop, MD
(1) Memory Research Resource Center for Alzheimer’s disease, University Hospital Montpellier, France (2) Alzheimer’s Disease Clinical Research Centre, Gérontopôle, Toulouse University Hospital, France (3) Memory Clinic, University Hospital Lille, France (4) Memory Research Resource Center for Alzheimer’s disease, University Hospital La Timone, Marseille, France (5) Memory Center CHU E.A. CabiTel, University of Nice Sophia Antipolis, Nice, France (6) Memory Research Resource Center for Alzheimer’s disease, University Hospital Pellegrin, Bordeaux, France (7) Memory Clinical Center CMRR Paris Nord Ile-de-France, Louis-Lanbiostere, Fernand Widal Hospital, AP-HP, Paris, France (8) Pharmexx SA, Issy-les-Moulineaux, France

P41: Phase I Study of a Novel Humanized Anti-Amyloid beta (Aβ) Aggregates Specific Antibody KHK6640 in Alzheimer’s Disease
Marc Cantillon, MD,1 Louise Wilson, MSc,2 Eri Ohta, PhD,3 Niels Prins, MD, PhD,1 Niels Andreassen, MD, PhD,1 Katsuyoshi Tsukii, MSc1 (1) Kyowa Kirin Pharmaceutical Development, Inc., USA (2) Kyowa Kirin Pharmaceutical Development, Ltd, UK (3) VUmc Alzheimer Center, Netherlands (4) Karolinska University Hospital, Sweden

Hiroyuki Shimada, MD,1 Kenichiro Sugiyama, Pharm.D,1 Yoshiumi Ouchi, MEng,2 Katsuyoshi Tsukii, MSc1 (1) Osaka city university hospital, Osaka, Japan (2) Kyowa Hakko Kirin Co, Ltd, Japan (3) Kyowa Kirin Pharmaceutical Development, Inc., USA
POSTER PRESENTATIONS

Late Breaking Posters

LBP25: A Study to Evaluate Safety, Tolerability and Pharmacokinetics of AD-35 Tablets Taken Orally in Healthy Chinese Subjects
Cuibai Wei, PhD, MD1, Jianping Jia, PhD, MD1, Tingting Li, MS1, Wei Wang, MD1, Tingting Hou, MD1, Xiu Wang, MD1, Hui Xu, MD1
(1) Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, P.R. China.

LBP26: The use of transdermal Rivastigmine in the treatment of Alzheimer's disease
Gustavo Alves Andrade dos Santos
SENAC University Center, São Paulo, Brazil

LBP27: Title: NILVAD: A phase III clinical trial of nilvadipine in mild to moderate Alzheimer’s disease - results of subgroup analyses.
Michael Mullan, MBBS, PhD1, Laila Abdullah, PhD1, Fiona Crawford, PhD2, Ricardo Segurado, PhD2, Suzanne Hendrix, PhD2, Brian Lawlor, MBBS5. The NILVAD consortium.
(1) Archer Pharmaceuticals, Sarasota, FL, USA; (2) University College Dublin, Dublin, Ireland; (3) Pentara Corporation, Soft Lake City, UT, USA; (4) Trinity College Dublin, Dublin, Ireland

LBP28: Biomarker Outcomes from the Phase Ib/2a Safety Trial of the Anti-ß Oligomer Drug CT1812 in Alzheimer’s Patients
Susan M. Catalano, PhD1, Lon S Schneider, MD, MS1, Steven DeKoshy, MD1, Roger Morgan, MD1, Courtney Rehalt1, Kelsie Mozzi1, Nicholas I Izzo, PhD1, Michael Grundman, MD, MPH1,2, Michael Schirm, PhD2, Rudolf Guibaud, MSc1, Daniel Chelsky, PhD7
(1) Cognition Therapeutics Inc., Pittsburgh, PA, USA; (2) Global R&D Partners, LLC, San Diego, California USA; (3) Kecti School of Medicine of USC, Los Angeles, CA, USA; (4) McKnight Brain Institute, University of Florida, Gainesville, FL, USA; (5) MedSurge, LLC Raleigh, North Carolina, USA; (6) Aclairo Pharmaceutical Development Group, Inc. Vienna, VA, USA; (7) Caprion Biosciences, Inc., Montreal, Canada

LBP29: UB-311 active vaccine generates titers specific for Aß oligomers and fibrils without evidence of ARIA-E or encephalopathy in a completed Phase 1 and an ongoing Phase 2a study in Alzheimer’s disease.
Ajay Verma1, Paul Maruff2, A. Schembri2, P. N. Wang3, M. J. Chiur4, C. C. Huang5, C. C. Chang6, H. C. Chen1, P. Chang1, C. Y. Wang1
(1) United Neuroscience, Inc. Hauppauge, NY, USA; (2) Cogstate Limited, Melbourne, Victoria, Australia; (3) Department of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan; (4) Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan; (5) Department of Neurology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; (6) Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

LBP30: Multiparameter Analyzes of Progression from Mild Cognitive Impairment to Alzheimer’s Dementia: A 10 Year long-term Follow-Up Study
Oliver Peters MD1, Dominik Diesing MD2, Stefan Klöppel MD2, Johannes Kornhuber MD1, Roberto Goya MD3, Jens Willfang, MD4, Isabella Heuser, MD, PhD1
(1) Department of Psychiatry, Charité, Berlin, Germany; (2) Department of Psychiatry, Bern, Switzerland; (3) Department of Psychiatry, Erlangen, Germany; (4) Department of Psychiatry, Göttingen, Germany

LBP31: Single Ascending Dose Phase I clinical trial of PTI-125 in healthy volunteers
Lindsay H. Burns, PhD1, George J. Atiee, MD2, Michael Marsman, PharmD1 and Nadav Friedmann, PhD, MD1
(1) Pain Therapeutics, Inc., Austin, TX; (2) Worldwide Clinical Trials, San Antonio, TX

LBP32: Multiple Ascending Dose Study of the Tau-Directed Monoclonal Antibody BIIB092 in Patients with Progressive Supranuclear Palsy
Irfan Qureshi, MD1, Michael Grundman, MD, MPH2, Giridhar Tirucherai, PhD1, Clifford Bechtold, MS2, Michael Ahlijianian, PhD1, Gerry Kolaitis, MS1, Lawrence I. Golbe, MD1, Lawrence S. Honig, MD, PhD1, Stuart Isaacs, MD1, Murray Grossman, MD EdD1, Nikolaus R. McFarland, MD, PhD1, Irene Litvan, MD1, David S. Geldmacher, MD2, Tao Xie, MD, PhD2, Vytte Bordelon, MD, PhD2, Paul Tuile, MD2, Padraig O’Suilleabhain, MD3, Theresa Zesiewicz, MD1, Adam Boxer, MD, PhD4
(1) Bristol-Myers Squibb, Lawrenceville, NJ, USA and Watlington, CT, USA; (2) Global R&D Partners, LLC, San Diego, CA, USA; (3) Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA; (4) Columbia University Medical Center, New York, NY, USA; (5) Bocar Ratan Institute for Neurodegenerative Disorders, Boca Raton, FL, USA; (6) University of Pennsylvania, Philadelphia, PA, USA; (7) University of Florida, Gainesville, FL, USA; (8) University of California, San Diego, CA, USA; (9) University of Alabama at Birmingham, Birmingham, AL, USA; (10) University of Chicago, Chicago, IL, USA; (11) University of California, Los Angeles, CA, USA; (12) University of Minnesota, Minneapolis, MN, USA; (13) University of Texas Southwestern Medical Center, Dallas, TX, USA; (14) University of South Florida, Tampa, FL, USA; (15) University of California, San Francisco, CA, USA
**Theme 11. New therapies and clinical trials**

**P114:** A novel approach to the therapy of Alzheimer’s disease based on peptide nanoliposome inhibitors of Aβ and tau aggregation  
*David Allsop, PhD¹,², Mark Taylor, PhD³,² Nigel Fullwood, PhD¹, Maria Michael¹ Anthony Aggidis¹, Shoonan Vincent, PhD², Mark Dale, MD²*  
¹ Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK ² Peptide Innovations Limited, Affiliated Company of MAC Research, Blackpool, UK

**P115:** Alzheimer’s disease drug development pipeline: 2017  
*Jeffrey Cummings¹, Garam Lee¹, Travis Mortsdorf¹, Aaron Ritter¹, Kate Zhong¹*  
¹ Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA ² Touro University Nevada, Henderson, NV, USA ³ Global Alzheimer Platform, Washington, D.C., USA

**P116:** The influence of a mobility training program on gait performance among healthy cognitive elderly people and people with MCI  
*Carine Federspiel, MD¹,², Elisabeth Bourhel, PhD¹ Jean-Paul Steinmetz, PhD¹,²*  
¹ Centre for memory and mobility, Luxembourg (2) ZithaSenior, Research & Development, Luxembourg

**P117:** Pre-clinical and first clinical data of an orally available amyloid beta oligomer eliminating compound that enhances cognition and impedes neurodegeneration in various Alzheimer’s disease mouse models  
*Dieter Willbold¹,², Janine Kutzsche², Manfred Windisch³, Dagmar Jürgens²*  
¹ Institut für Physikalische Biologie, Heinrich-Heine-Universität, Düsseldorf, Germany ² Institute of Complex Systems, ICS-6: Structural Biochemistry, Research Centre Jülich, Jülich, Germany ³ Neuroscios, Graz, Austria

**P118:** Informed Consent Ensuring Access to Anonymized Patient-Level Data and Biospecimen is Critical to Accelerating Innovative Alzheimer Disease Treatments  
*Stephen P. Arnerić, PhD¹, Penny A. Dachs, PhD¹, Ann Marie Hahe, MD¹, James Hendrix, PhD¹, Monica Moreno¹, Lisa A. Gold, PhD¹, Dagmar Theis, PhD², Mark F. Gordon, M.D.², Vollter D. Kern, PhD³, George Vradenburg⁴*  
¹ Critical Path Institute, Tucson, AZ, USA ² American Epilepsy Society, Chicago, IL, USA ³ Eli Lilly and Company, Indianapolis, IN, USA ⁴ Alzheimer’s Association, Chicago, IL, USA ⁵ Merck, West Point, PA, USA ⁶ Boehringer-Ingelheim, Vienna, Austria ⁷ Advisor, CT, USA ⁸ US Against Alzheimer’s, Washington, DC, USA

**P119:** Novel strategies against Alzheimer’s Disease using induced human neuronal progenitors and neuronal cells  
*Ying Lei, PhD¹, Gang Li, MD, PhD¹, Ying Chen, PhD², Ge Gao, MD, PhD² and Jian Zhao, PhD²*  
¹ GMP Center of Stem Cell Engineering, Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China ² IxCell Biotechnology Co., Ltd, Shanghai, China

**P121:** P38α kinase inhibition appears to lead to reduction in amyloid-beta generation in patients with Early Alzheimer’s disease  
*Philip Scheltens MD PhD¹, Niels Prins MD PhD¹, Adriaan Lammertsma PhD², Maqsood Yaqub PhD², Hui-May Chu PhD², Bart van Berckel MD PhD², John Alam MD²*  
¹ Department of Neurology and Alzheimers Center, VU University Medical Center; and the Alzheimers Research Center (ARC), Amsterdam, NL ² Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, NL ³ Anoixis Corporation, Natick, MA, USA; ⁴ EIP Pharma LLC, Cambridge, MA, USA

**P122:** ACD678, A novel gamma-secretase modulator for the treatment of Alzheimer Disease  
*Bengt Winblad¹, Johan Lundhvidt¹, Helena Karlström¹ Magnus Halldin², Johan Sandin², Gunnar Nordvall²*  
¹ Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden ² AlzeCure Pharma AB, Huddinge, Sweden
**POSTER PRESENTATIONS**

**Wednesday, November 1 and Thursday, November 2**

**P123: Demonstration of blood-brain-barrier (BBB) penetration and brain target engagement for neflamapimod (p38α kinase inhibitor) in patients with early Alzheimer’s disease (AD)**

John Alam¹, Charlotte Teunissen²

(¹) EIP Pharma LLC, Cambridge, MA, USA (²) Department of Clinical Chemistry, VU University Medical Center, Amsterdam, NL

**P124: ACD855, development of a positive modulator of neurotrophin signaling for the treatment of Alzheimer’s Disease**

Pontus Forsell, PhD², PhD, Gunnar Nordvall², PhD, Johan Lundtwist², PhD, Magnus Haalddin², PhD, Märta Dahlström¹, M.Sc. and Maria Erirotsdotter¹, MD, Prof, and Johan Sandin², PhD

(¹) AlzeCure Foundation, Karolinska Institutet Science Park, Huddinge, Sweden (²) AlzeCure Pharma AB, Huddinge, Sweden (³) Dept of Neurobiology, Care Sciences and Society, Karolinska Institute, Sweden (⁴) Dept Geriatric Medicine, Karolinska university hospital, Huddinge, Sweden

**P125: Pharmacokinetics and Delivery to the Brain in Rats of P8, a Peptide Drug Candidate for the Treatment of Alzheimer’s Disease**

Nazneen N. Dewji¹, S. Jonathan Singer¹, Leah Hanson¹, William Frey¹, Bruce Morimoto¹, David Johnson², Daniel Dolan³, Marc R. Azar⁰

(¹) Cenna Biosciences Inc., La Jolla, CA, USA (²) Department of Medicine, UC San Diego, La Jolla, CA, USA (³) Division of Biological Sciences, UC San Diego, La Jolla, CA, USA (⁴) Health Partners Institute, St. Paul, MN, USA (⁵) Celeron Inc., USA (⁶) MicroConstants, San Diego, CA, USA (⁷) Behavioral Pharma, La Jolla, CA, USA

**P126: The ABCA-1 agonist CS6253 that reverses apoE4-driven Alzheimer’s disease brain phenotype and cognition decline lowers plasma Neurofilament-light concentrations.**

Jan O Johansson¹, Anat Boehm-Cagan², Henriët Zetterberg³, Kaj Blennow⁴, John K. BIELICKI⁹, Daniel M. Michaelson²

(¹) Artery, Therapeutics, Inc., San Ramon, CA, (²) Tel Aviv University, Tel Aviv, Israel, (³) Department of Psychiatry and Neurochemistry, (⁴) Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden, (⁵) Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, (⁶) Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK, (⁷) UK Dementia Research Institute, London, UK, (⁸) UC Berkeley, Berkley, CA

**P127: Novel modulators of molecular chaperone network for the treatment of Alzheimer Disease**

Pavel Pavlov PhD, Bengt Winblad MD, PhD, Rajnish Kumar PhD

Karolinska Institutet, Dept of Neuroscience and Society, Div of Neurogeriatrics, Huddinge, Sweden

**P128: Cerebral Energy Deficit in Mild to Moderate Alzheimer’s Disease: Strategies to Increase Brain Fuel Supply**

Christian-Alexandre Castellano, PhD, Etienne Croteau, PhD, Melanie Fortier, MSc, Christian Bocci, MD, Tamas Fulop, MD, Guy Lacombe, MD, Nancy Paquet, MD, Isabelle Dionne, PhD and Stephen Cunnane, PhD

(¹) Research Center on Aging, CHUSS – CHUS, Sherbrooke, QC, Canada (²) Pharmacology-Physiology department, FMSS, University of Sherbrooke, QC, Canada (³) Medicine department, FMSS, University of Sherbrooke, QC, Canada (⁴) Nuclear medicine department, FMSS, University of Sherbrooke, QC, Canada (⁵) Faculty of physical education and sports, University of Sherbrooke, QC, Canada

**P129: Pharmacokinetic and target engagement (TE) analysis of BIIBO76 in cynomolgus monkeys**

Weiping Chen, Julie Czerkowicz, Qin Wang, Danielle Graham

Biogen Inc. Cambridge, MA, USA

**Late Breaking Posters**

**LBP15: SUVN-502 + Donepezil + Memantine (Triple combination) represents a promising new approach for symptomatic treatment of Alzheimer’s disease.**

Ramakrishna Nirogi, PhD, Renny Abraham, PhD, Vijay Benade, MS, Pradeep Jayarajan, PhD, Koteshwar Mudigonda, PhD, Jyothsna Raval, MS, Devender Reddy Ajjala, PhD, Ramasastry Kambhampati, PhD, Trinath Reddy Bandyala, PhD and VentakatJastal MS

(¹) Discovery Research, Suven Life Sciences Ltd, Hyderabad, India

**LBP16: Neuroprotective and trophic effects of Bacopa monniera extract protects against amyloid β-peptide and hydrogen peroxide-induced toxicity and oxidative stress**

Manjeet Singh and Charles Ramassamy

(¹) INRS- Institut Armand Frappier, Laval, Quebec, Canada
LBP17: Phase 1 Study of the Muscarinic M1 Positive Allosteric Modulator VU319 for Alzheimer’s Disease: Exploration of Novel Markers of Target Engagement
Paul A Newhouse, MD; Alexandra Key, PhD; Alexander Conley, PhD; Robert Gould, PhD; Carrie Jones, PhD

(1) Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center (2) Vanderbilt Kennedy Center, Vanderbilt University (3) Vanderbilt Center for Neuroscience Drug Discovery, Department of Pharmacology, Vanderbilt University

LBP18: Efficacy and safety of the Chinese medicine SaiLuoTong in vascular dementia: A randomised, controlled, double-blind, parallel-arm trial

(1) Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China. (2) Beijing Key Laboratory of Geriatric Cognitive Disorders; Beijing, China. (3) Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China. (4) Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China. (5) National Clinical Research Center for Geriatric Disorders, Beijing, China. (6) Department of Gerontology, Fuxing Hospital, Capital Medical University, Beijing, China. (7) Department of Health Statistics, Second Military Medical University, Shanghai, China. (8) Department of Neurology, Daping Oilfield General Hospital, China. (9) Department of Neurology, Henry Ford Hospital, Detroit, USA. (10) Centre for Studies in Aging, McGill University, Montreal, CAN.

LBP19: Increased immune signaling predicts mitigation in AD clinical outcomes – an alternate route to prevention.
John Breitner, MD, MPH (1) Douglas Hospital Research Centre, Montreal, QC, Canada; (2) McGill University Faculty of Medicine

LBP20: CHARACTERISTICS OF SLEEP AND WAKEFULNESS MEASURED WITH ACTIGRAPHY IN PATIENTS WITH IRREGULAR SLEEP-WAKE RHYTHM DISORDER AND ALZHEIMER’S DISEASE.
Margaret Moline, PhD; Patricia Murphy, PhD; Gleb Filippov, MD, PhD; Naoki Kubota, MPH; Mohammad Bsharat, PhD; Manuel Kemethofer, MSc; Andrew Satlin, MD

(1) Eisai, Inc., Woodcliff Lake, NJ, USA (2) Eisai Co., Ltd. Tokyo, Japan (3) The Siesta Group, Vienna, Austria

LBP21: MULTIPLE ASCENDING DOSE STUDY WITH A PRODRUG OF GALANTAMINE: A PHARMACO-EEG ANALYSIS WITH EVIDENCE OF POSITIVE EFFECTS ON COGNITION.
D.G. Kay, PhD; E. Hart, PhD; C. Baktter, MD; A. Maeliche, PhD; Sonja Simpraga; Klaus Linkenhaer-Hansen; Simon-ShlomoPoll; G.J. Groeneveld, MD, PhD

(1) Neurodyn Cognition Inc., Charlottetown, PE, Canada; (2) Centre for Human Drug Research (CHDR), Leiden, the Netherlands; (3) Galantos Pharma, Nieder-Olm, Germany; (4) Vrije Universiteit Amsterdam, the Netherlands; (5) NSI Analytics BV, Amsterdam, the Netherlands

LBP22: Matrix therapy, a novel approach for Alzheimer’s disease and related tauopathies
Dulce Papy-Garcia, PhD; Growth, Repair and Regeneration of Tissues Research Unit (CRRET-CNRS 9215, Université Paris Est Créteil, Créteil, France; Mohand-Ouidir Ouidja, MD; Robert Gould, PhD; Denis Barrittault, PhD

(1) CRRET-CNRS 9215, Université Paris Est Créteil, Créteil, France (2) OTR3, Paris, France

LBP23: ALLOPREGNANOLONE AS A REGENERATIVE THERAPEUTIC FOR ALZHEIMER’S DISEASE: PHASE IB/2A OUTCOMES
Robert Diaz Brinton, PhD; Gerson Hernandez, MD; Christine Solinsky, PharmD; Meng Law, MD; Yonggang Shi, PhD; Dogu Aydogan, PhD; Jin Gahm, PhD; Wendy Mach, PhD; Naoto Kono, MPH; Kathleen Rodgers, PhD; Claudia Lopez; Ronald Irwin, PhD; Michael Rogawski, MD; Chun-Yi Wu, PhD; Lon Schneider, MD

(1) Center for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, AZ, USA (2) Center for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, AZ, USA (3) Department of Clinical & Experimental Therapeutics, University of Southern California, Los Angeles, CA, USA (4) Department of Neuromedics, University of Southern California, Los Angeles, CA, USA (5) Laboratory of Neuro Imaging, USC Stevens Neuronmaging and Informatics Institute, University of Southern California, Los Angeles, CA, USA (6) Laboratory of Neuro Imaging, USC Stevens Neuronmaging and Informatics Institute, University of Southern California, Los Angeles, CA, USA (7) Laboratory of Neuro Imaging, USC Stevens Neuronmaging and Informatics Institute, University of Southern California, Los Angeles, CA, USA (8) Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA (9) Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA (10) Center for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, AZ, USA (11) Center for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, AZ, USA (12) Department of Pharmacology, University of Southern California, Los Angeles, CA, USA (13) Department of Neurology, University of California at Davis, Davis, CA, USA (14) Department of Neurology, University of California at Davis, Davis, CA, USA (15) Department of Psychiatry, University of Southern California, Los Angeles, CA, USA
**Theme 3. Clinical trials: Imaging**

**P43:** France adopts a 3D diagnosis strategy for its National Alzheimer databank – An optimization of patient selection for clinical trials  
**Pierre Krolak-Salmon**, MD, PhD; Philippe Robert, MD, PhD; Eric Assema; MD, Claudine Bert, MD, PhD; Mathieu Ceccaldi, MD, PhD; Bruno Dubois, MD, PhD; Stephane Epelbaum, MD, PhD; Bruno Vellas, MD, PhD; Audrey Gabelle, MD, PhD  
(1)Clinical and Research Memory Centre of Lyon, Hospices civils de Lyon, University Lyon 1, INSERM U1028, UMR CNRS 5292, Lyon, France (2)Clinical and Research Memory Centre of Nice, France (3)Memory Clinic Alpes Nord, France (4)Inserm U968, University of Montpellier, 34093 Montpellier, France (5)Clinical and Research Memory Centre of Paris Prat-Salpêtrière, France (6)Clinical and Research Memory Centre of Toulouse, France (7)Clinical and Research Memory Centre of Montpellier, France

**P44:** Divergent topological networks of grey and white matter in Alzheimer’s disease: A diffusion kurtosis imaging analysis  
**Jun Xu**, MD, Hongying Zhang, MD, Jiaxing Cheng, MD  
(1)Neurology Department, Northern Jiangsu People’s Hospital, Yangzhou University, Yangzhou, China (2)Radiology Department, Northern Jiangsu People’s Hospital, Yangzhou University, Yangzhou, China

**P45:** Impact of two distinct MRI parallel imaging implementations on hippocampal volume estimates obtained from two methodologically different methods  
**Oliver Peters, MD; Per Suppa, MD; Catharina Lange, MSC; Ralph Buchert, PhD; Lothar Spies, PhD; Isabella Heuser, MD, PhD  
(1)Department of Psychiatry, Charité, Berlin, Germany (2)jung diagnosics GmbH, Hamburg, Germany (3)Department of Nuclear Medicine, Charité, Berlin, Germany (4)Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Germany

**P46:** MRI markers of neurodegeneration in preclinical Alzheimer’s disease  
**Adam J. Schwarz, PhD; Michael G. Case, MS; Peter F. Castelluccio, MS  
(1)Department of Psychiatry, Charité, Berlin, Germany (2)jung diagnosics GmbH, Hamburg, Germany (3)Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Germany

**P47:** FDA Qualification of Intracranial Adjusted Hippocampal Volumetric Magnetic Resonance Imaging (ICV-HV vMRI) as a Prognostic Biomarker for Pre-Dementia Clinical Trials for Alzheimer disease Therapeutics  
**Daniela J. Conrado, PhD; Klaus Romero, MS; MD; Derek L. Hill, PhD; Patricia Cole, MD, PhD; Dawn Matthews, PhD; Gerald Novalt, MD; Volker D. Kern, PhD; Robin Wolz, PhD; Richard Meibach, PhD; Jackson Burton, PhD; Brian Corrigan, PhD; Timothy Nicholas, PhD; Danny Chen, PhD; Julie Stone, PhD; Viitram Sinha, PhD; Brian Willis, PhD; Wenping Wang, PhD; Stephen P. Arneric, PhD  
(1)Critical Path Institute, Tucson, AZ, USA (2)University of California, San Diego, CA, USA (3)Advisor, MA, USA (4)XIICO, London, United Kingdom (5)Advisor, MA, USA (6)ADMDX, Chicago, IL, USA (7)Janssen Pharmaceuticals (16), Titusville, NJ, USA (8)Advisor, NJ, USA (9)Advisor, CT, USA (10)Advisor, PA, USA (11)Advisor, Indianapolis, IN, USA

**P48:** Cerebral Atrophy in Alzheimer’s Disease Patients: Effect of Combined Therapy Between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor, Choline Alphoscerate  
**Enea Traini, PhD; Anna Carotenuto, PhD; Angiola Maria Fasanaro, MD; Francesco Amenta, MD  
(1)Centre for Clinical Research, Telermedicine and Telepharmacy, University of Camerino, Camerino, (2)Alzheimer Evaluation Unit, National Hospital, “A. Cardarelli”, Naples, Italy

**P49:** Cerebral hypoperfusion is not associated with an increase in β-amyloid pathology  
**Ruben Smith, MD, PhD; Sebastian Palmqvist, MD, PhD; Hanna Ljung, MS; Tobias Cronberg, MD, PhD; Daniel Ransoor, PhD; Oshar Hansson, MD, PhD  
(1)Lund University, Clinical Memory Research Unit, Dept. of Clinical Sciences Malmö, Malmö, Sweden. (2)Shåne University Hospital, Dept. of Neurology, Lund, Sweden. (3)Lund University, Shåne University Hospital, Department of Clinical Sciences, Neurology, Lund, Sweden (4)Lund University, Shåne University Hospital, Department of Clinical Sciences Lund, Diagnostic Radiology, Lund, Sweden. (5)Shåne University Hospital, Memory clinic, Malmo, Sweden

**P50:** Optimized detection of disease and treatment effect in preclinical and prodromal autosomal dominant Alzheimer’s disease with imaging biomarkers  
**Dawn C. Matthews MS MM; Ana S. Lukic, PhD; Randolph D. Andrews MS; Miles M. Wernick, PhD; Stephen C. Strother, PhD; Tammie L. S. Benzinger, MD, PhD; Dominantly Inherited Alzheimer Network
P51: Cognitive Function and Prevalence of Amyloid Pathology in Frail Adults – The COGFRAIL Study
Sourdet S, MD, Soriano G, RD, Steinmeyer Z, MD, Delrieu J, MD, Osset PJ, MD, Vellas B, MD, PhD.
(1) Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.

P52: Hippocampal volume is weakly associated with amyloid beta levels in asymptomatic individuals at risk for Alzheimer’s disease: findings from the CHARIOT-PRO Sub-Study
(1) Vannsen Neuroscience LLC, California, USA (2) Vannsen Neuroscience LLC, New Jersey, USA (3) Neuroepidemiology and Ageing Research, Imperial College London, London, UK (4) MedAvance Inc., New Jersey, USA

P53: Impact on Sample Size and Screening Using Amyloid Visual Read versus Quantitative Values for Inclusion
Donald G. McLaren, PhD, Felix Carbonell, PhD, Alex P. Zijdenbos, PhD, Barry J. Bedell, MD, PhD.
(1) Biospective Inc, Montreal, Quebec, Canada (2) McGill University, Montreal, Quebec, Canada

P54: Automated voxel-based Tau PET quantitation in early Alzheimer’s Disease: Association of hippocampus masked SUVR with baseline cognition
Arthur Mikhno, PhD, Janos Redei, MD, PhD, John Mann, MD, Ramin Parsley, MD, PhD.
(1) CDx, Inc., San Francisco, CA, USA (2) Columbia University, New York, NY, USA (3) New York State Psychiatric Institute, New York, NY, USA (4) Stony Brook University, Stony Brook, NY, USA

P55: Inter and Intra PET Scanner Variability in Multi-Center Clinical Trials Using the Hoffman Phantom
Katarzyna Adamczuk, PhD, Beth Gorman, BS CNMT, Maureen Runtke, BS CNMT, Nicolas Pannetier, PhD, David Scott, PhD, Joyce Suhy, PhD.
(1) Bioclinica, Newart, CA, USA; (2) Bioclinica, Philadelphia, PA, USA

Late Breaking Posters

LBP35: CROSS-SECTIONAL ASSOCIATIONS BETWEEN TAU PATHOLOGY BURDEN MEASURED BY [18F]GTP1 PET IMAGING AND COGNITION IN AD
Michael Ward, PhD, Sandra Sanabria Bohorquez, PhD, Paul T. Manser, PhD, Edmond Teng, MD PhD, Gai Ayalon, PhD, Kristin R. Wildsmith, PhD, Geoffrey A. Kerchner, MD PhD, Robby M. Weimer, PhD.
(1) Early Clinical Development, (2) Clinical Imaging Group, (3) Biostatistics, (4) Department of Neuroscience, (5) Biomarker Development, (6) Department of Biomedical Imaging; all Genentech, Inc., South San Francisco, CA, USA

LBP36: Retinal Hyperspectral Imaging for Early Diagnosis of Alzheimer’s Disease
Swati S. More, James M. Beach, Robert Vincen
Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, MN

LBP37: Simplified Non-Invasive Tracer Kinetic Analysis for 18F-Florbetaben PET using a Dual Time-Window acquisition protocol
Andrew W. Stephens, MD, PhD, Henryk Barthel, MD, PhD, Santiago Bullich, PhD, Norman Koglin, PhD, Georg A. Becker, PhD, Aleksandar Jovaletic, PhD, Susan De Santi, PhD, Osama Sabri, MD, PhD.
(1) Piramal Imaging GmbH, Berlin, Germany (2) Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany (3) Piramal Pharma Inc., Boston, MA, USA

LBP38: Voxel-wise determination of thresholds for amyloid and tau positivity using PET may improve the population enrichment of clinical trials
Tharick A. Pascoal MD, Suthana Mathotaarachchi MSc, Min Su Kang BSc, Joseph Ththerriault, Monica Shin MSc, Andrea L. Benedet MSc, Sara Mohades BSc, Jean-Paul Soucy MD, MSc, Serge Gauthier MD, FRCPC, and Pedro Rosa-Neto MD, PhD for the Alzheimer’s Disease Neuroimaging Initiative.
(1) Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, Alzheimer’s Disease Research Unit, Douglas Hospital, McGill University, Montreal, Canada (2) Department of Neurology and Neurosurgery, McGill University, Montreal, Canada (3) Montreal Neurological Institute, Montreal, Canada (4) PERFORM Centre, Concordia University, Montreal, Canada.
Friday, November 3 and Saturday, November 4

Theme 4. Clinical trials: Biomarkers including plasma

P56: Development of computational tools to improve the design of clinical trials of possible therapies for Alzheimer’s disease
Christoforos Hadjidjivassilou, PhD1, Alison Ower, MSc1, Stephanie Evans, PhD1, Kevin McRae-McKee, MSc1, Mei Mei Wong, PhD1, Frank de Wolf, MD, PhD2, Roy M. Anderson, PhD3
(1) Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, United Kingdom (2) Janssen Prevention Center, Leiden, The Netherlands

P57: PiB-PET as a standard for evaluating the clinical accuracy of diagnosing the clinical diagnosis of Alzheimer’s disease with plasma biomarkers
Che-Chuan Yang, PhD1, Ming-Jang Chiu, MD, PhD2, Ta-Fu Chen, MD, PhD3 and Shieh-Yueh Yang, PhD4
(1) MagQu Co., Ltd, New Taipei City, Taiwan (2) Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taiwan (3) Department of Neurology, Renai Branch, Taipei City Hospital, Taipei, Taiwan (4) Department of Neurology, En Chu Kong Hospital, New Taipei City, Taiwan (5) MagQu Co., Ltd, New Taipei City, Taiwan

P58: A cross-validation study on plasma biomarker study in clinical practice for diagnosing Alzheimer’s disease
Ming-Jang Chiu, MD1,2, Ta-Fu Chen, MD,1 Chaor-Jong Hu, MD,2, Sui-Hing Yan, MD,2, Yu Sun, MD,2, Bing-Hsien Liu, PhD2, Yun-Tsui Chang, MS3, Che-Chuan Yang, PhD, and Shieh-Yueh Yang, PhD4
(1) Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan (2) Department of Neurology, Taipei Medical University, Shuang-Ho Hospital, New Taipei City, Taiwan (3) Department of Neurology, Renai Branch, Taipei City Hospital, Taipei, Taiwan (4) Department of Neurology, En Chu Kong Hospital, New Taipei City, Taiwan

P59: Brain ABCA-1 activity and ApoE lipidation are reduced in APOE4 and with cognitive impairment.
H.N. YASSINE1, V. RAWAT1, A. BOEHM-CAGAN2, A. N. FONTEH3, J. JOHANSSON4, J. BIELICKI5, H. C. CHUI, D. M. MICHAELSON6, M. G. HARRINGTON7
(1) USC, Los Angeles, CA; (2) Tel Aviv Univ., Herzliya, Israel; (3) Huntington Med. Res. Inst., Pasadena, CA; (4) Artery Therapeut., San Ramon, CA; (5) UC Berkeley, Berkeley, CA; (6) Tel-Aviv Univ., Tel-Aviv, Israel

P60: Analysis of Macular thickness and retinal nerve fiber layer by using of spectrum domain-optical coherence tomography in patients with Alzheimer’s disease and amnestic mild cognitive impairment
Kyung-Hoon Shin, MD1, Do-Gyun Kim, MD, PhD, Bon D Ku, MD3
(1) Department of Ophthalmology, Kim’s Eye’s Hospital, Konyang University, South Korea (2) Department of Ophthalmology, Myongji Hospital, Seonam University College of Medicine, South Korea (3) Department of Ophthalmology, International St. Mary’s Hospital Institute for Translational & Clinical Research College of Medicine Catholic Kwandong University, South Korea

P61: Levels of cerebrospinal fluid biomarkers total tau and phosphorylated tau do not predict survival time after diagnosis of Alzheimer’s disease – An 18-year follow-up
Carina Wattimo, RN, BSc, PhD1, Kai Blennow, MD, PhD, Lennart Minthon, MD, PhD, Oskar Hansson, MD, PhD1
(1) Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden (2) Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy, University of Gothenburg, Malmö, Sweden

P62: An Amyloid Blood Biomarker for Preclinical Alzheimer’s Disease
Klaus Gerweng, Prof., PhD1, Andreas Nabers, PhD, Julia Lange1, Jonas Schartner, PhD, Jörn Güldenhaupt, PhD1
(1) Department of Biophysics, Ruhr-University Bochum, Germany

P63: Effects of APOE4 on neuroimaging, biomarkers and clinical characteristics of prodromal Alzheimer’s disease
Niklas Matsson, MD, PhD1,2,3, Oscar Eriksson, MD1, Olof Lindberg, PhD1, Michael Schöll, PhD1,4, Björn Lampinen, PhD1, Markus Nilsson, PhD1, Philip S. Insell,7,8, Ronald Lautner, MD9,10, Olof Strandberg, PhD1, Danielle van Westen, MD, PhD1, Henrik Zetterberg, MD, PhD10,11, Kaj Blennow, MD, PhD9,10, Sebastion Palmqvist, MD, PhD12, Eric Stomrud, MD, PhD13, Oskar Hansson, MD, PhD14
(1) Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden (2) Memory Clinic, Skåne University Hospital, Malmö, Sweden (3) Department of Neurology, Skåne University Hospital, Lund, Sweden (4) MedTech West and the Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden (5) Department of Clinical Sciences, Lund Medical Radiation Physics, Lund University, Lund, Sweden (6) Lund University, Skåne University Hospital, Department of Clinical Sciences, Lund, Diagnostic Radiology, Lund, Sweden (7) Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Cener, San Francisco, CA, USA (8) Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA (9) Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Malmö, Sweden (10) Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Malmö, Sweden (11) Department of Molecular Neuroscience, UCL Institute of Neurology
**P64: Low Total Aβ42/40 Plasma Ration in MCI Patients is Associated with a FDG-PET Pattern Suggestive of AD and Predicts Progression to Dementia.**  
Virginia Pérez-Griñalba1, Judith Romero1, Pedro Pesin1, Leticia Sarasa1, Itziar San-José1, Javier Arbizu2, Lluis Tàrraga3, Agustín Ruiz2, Mercé Boada4, Manuel Sarasa1 and The AB255 Araclon Group5  
(I)Araclon Biotech S.L., Zaragoza, Spain (2) Clínica Universitaria de Pamplona, Pamplona, Spain (3) Alzheimer Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades. Barcelona, Spain (4) www.araclon.com

**P65: Beta Amyloid Anti-Oligomer Action of ALZ-801 and Clinical Dose Translation Analyses Support Confirmatory Phase 3 Program in Alzheimer’s Disease**  
J.A. HEY, PhD1, P. KOCIS, PhD1, S. ABUSHAKRA, MD1, J. YU, MD, PhD1, A. POWER, MD1, K. BLENNOWN, MD2, M. TOLAR, MD, PhD2  
(1)ADx NeuroSciences N.V., Framingham, MA, USA; (2)University of Gothenburg, Mölndal, Sweden

**P66: Elecsys CSF Biomarkers Predict Clinical and Cognitive Outcomes**  
Chenqie Xiong2,3,4, PhD, Dean Coble2, PhD, Julia D. Gray7,8, BS, Elizabeth Grant2, PhD, Lena McCue2,3, PhD, John C. Morris2,3, MD, Jason Hassenstab9, PhD, Richard Batita9, MD, Udo Eichenlaub6, PhD, Katharina Zinth4, MSc, Sandra Rutz2, PhD, Marian Quan1, BS, MBA, Anne M. Fagan1,2, PhD (1) Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (2)Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA (3)Department of Psychology, Washington University School of Medicine, St. Louis, MO, USA (4) Department of Mathematics, Washington University, St. Louis, MO, USA (5) Roche Diagnostics International, Rotkreuz, Switzerland (6) Roche Diagnostics GmbH, Penzberg, Germany (7) Roche Diagnostics Operations, Indianapolis, IN, USA

**P67: The evaluation of novel monoclonal antibodies targeting different forms of Neurofilament Light in brain and CSF**  
Ann De Vos, PhD1, Dirk Jacobs, Eng1, Nele Dewit, BSc1, Carola Schipke, MD, PhD2, Olivier Persers, MD, PhD2, Eugeen Vanmechelen, PhD1  
(1)ICDD, Gemenos, France; (2) IRCCS Fatebenefratelli, Brescia, Italy

**P68: Conversion prevalence among pre-dementia AD patients and risk factors**  
Beatrice Blanc, PhD1,2, PhD, Clotilde Biscarra1, Pauline Martinasso1, Samantha Galluzzi, MD1, Moira Marizzoni PhD1, Jorge Jovicich PhD2, Giovanni B. Frisoni MD2,6, Gianluigi Forloni PhD1, Diego Albani MSc1, Jill Richardson PhD1, Lucilla Parnetti MD, PhD2, Magda Tsolali MD, PhD2, Flavio Nobili MD2, David Bartre-Faz PhD2, Mira Didic MD4, Peter Schoenhnecht MD4, Pierre Payoux, MD, PhD4, Andrea Soricelli MD4, Paolo M Rossini MD, PhD4, Pieter Jelle Visser MD1,4, Regis Bordet MD, PhD2,4, Ute Fiedler PhD2, Olivier Blin MD, PhD2,4, Joëlle Micalle2, Laura Lanteaume22, Nathalie Sambuchi, PhD2,3, Isabelle Muraccioli2,3, Elizabeth Jouve2, Bernard Michel, MD, PhD2,3, Nathalie Compagnone, PhD2,3  
(I) ICDD, Cemmenos, France; (2) IRCCS Fatebenefratelli, Brescia, Italy (3) University Hospitals and University of Geneva, Geneva, Switzerland (4) University of Trento, Trento, Italy (5) Mario Negri Institute for Pharmacological Research, Milan, Italy (6) GSK, Stevenage, UK (7) Ospedale Santa Maria della Misericordia, Perugia, Italy. (8) G. Papanikolaou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. (9) University of Genoa, Genoa, Italy. (10) University of Barcelona and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain. (11) Hôpital Timone Adults, Marseille, France. (12) Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany. (13) CHU de Toulouse, Toulouse, France (14) SDN Istituto di Ricerca Diagnostica e Nucleare, Naples, Italy. (15) Catholic University, Rome, Italy. (16) Alzheimer Centre, VU Medical Centre, Amsterdam, the Netherlands (17) University of Lille, Inserm, CHU Lille, L117 - Lille, France. (18) Faculty of Medicine, LVR-Hospital Essen, University of Duisburg-Essen, Essen, Germany. (19) Aix-Marseille Univ., Marseille, France. (20) CHU la Timone, Marseille, France (21) Hospital Sainte Marguerite, Marseille, France, (22) Hôpital de la Conception, Marseille, France

**P69: Conversion prevalence among pre-dementia AD patients and risk factors**  
J.A. HEY, PhD1, P. KOCIS, PhD1, S. ABUSHAKRA, MD1, J. YU, MD, PhD1, A. POWER, MD1, K. BLENNOWN, MD2, M. TOLAR, MD, PhD2  
(1)ADx NeuroSciences N.V., Gent, Belgium (2) Charité-Universitätsmedizin Berlin, Memory Clinic at the ECRC, Berlin, Germany

**P70: Sex-specific changes in levels of circulating brain-enriched microRNAs during normal aging and different stages of Alzheimer’s disease**  
Kira Sheinerman, PhD1, Anne Fagan, PhD2, Elizabeth Grant, PhD2, Aabhas Mathur2, Debra Kessler, RN1, Beth Shaz, MD1, Jon Toledo, MD, PhD1, David Woltz, MD3, John Trojanowski, MD, PhD1, Vladimir Tsivinsky, PhD4, Samuil Umansty, MD, PhD1  
(1) DiamiR Biosciences, Monmouth Junction, NJ, USA (2) Neurology Department, Washington University in St. Louis, MO, USA (3) New York Blood Center, New York, NY USA (4) Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
P71: European validation of the PLM-scale, a cerebrospinal fluid biological scale for positive Alzheimer’s disease diagnosis.
Audrey Gabelle1, Sebastiaan Engelborgh2, Koen Poesen3, Panos Alexopoulos4, Martin Vynhalek5, Julien Dumurgier6, Vincent De la Sayette5, Susanna Schraen7, Stéphanie Bombois8, Mathilde Sauvée9, Jean-Louis Laplanche10, Jakub Hort11, J. Hugon11, F. Pasquier12, Alzheimer’s Disease Neuroimaging Initiative, Sylvain Lehmann13 and Claire Paquet6
(1) Memory Resources and Research Center of Montpellier, Department of Neurology, CHU de Caumont, and Montpellier University and IRMBe, Inserm U1183, Montpellier, France; (2) University of Antwerp (UA), Belgium; (3) laboratorium voor Molecuul Neurobiomarker Leuven; (4) Universität Rostock, Rostock, Germany; (5) 2nd Faculty of Medicine and Molot University Hospital, Czech Republic; (6) International Clinical Research Center, St. Anne’s University Hospital Brno, Brno, Czech Republic; (7) CMRR, Paris Nord Ile-de-France; (8) C.P. J.H. Inserm U839; (9) Paris 7 - Faculté de médecine Xavier Bichat, France; (10) CMRR de Caen, France; (11) University of Lille Nord de France, Lille University Hospital, INSERM U1172, Lille, France; (12) CMRR de Lille, University of Lille Nord de France, France; (13) CMRR de Grenoble, Grenoble, France; (14) Laboratoire de Biochimie Laroissoisier-Fernand Vidal Hospital, APHP, University Paris 7-Denis Diderot, University Paris Descartes, Paris, France; (15) Laboratoire de Protéomique clinique, Laboratoire de Biochimie and I2M, Inserm U1183, Montpellier, France.

P72: Elecsys® Total-Tau CSF and Elecsys® Phospho-Tau (181P) CSF (pTau) novel, fully automated immunoassays for rapid and accurate quantitation of CSF biomarkers for clinical use
Valeria Lipta, PhD; Ekaterina Manuilova, MSc; Christian Knop, PhD; Tobias Selle, PhD; Werner Kraus, PhD; Tobias Oelschlaegel, PhD; Lars Hillringhaus, PhD
(1) Roche Diagnostics GmbH, Penzberg, Germany.

P73: Concordance of the Elecsys® β-Amyloid (1-42) (Abeta42) cerebrospinal fluid (CSF), Total-Tau CSF (tTau) and Phospho-Tau (181P) CSF (pTau) immunoassays with amyloid-PET, and their association with clinical progression of Alzheimer’s disease.
Leslie M. Shaw, PhD; Kaj Blenlow, MD, PhD; Niklas Mattsson, MD PhD; John Seibyl, MD; Michal Figursti, PhD; John Q. Trojanowski, MD, PhD; Katharina Buch, PhD; Christina Rabe, PhD; Udo Eichenlaub, PhD; Sandra Rutz, PhD; Monika Widman, ChTtech; Maryline Simon, PhD; Oskar Hansson, MD PhD
(1) Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, PA, USA; (2) Clinical Neurochemistry Laboratory, Sahlgrensa University Hospital, Malmö, Sweden; (3) Clinical Memory Research Unit, Lund University, Malmö, Sweden; (4) Institute for Neurodegenerative Disorders, New Haven, CT, USA; (5) Genentech South San Francisco, USA; (6) Roche Diagnostics GmbH, Penzberg, Germany; (7) Roche Diagnostics, Mannheim, Germany; (8) Roche Diagnostics, Rotkreuz, Switzerland.

P74: Crenezumab pharmacokinetic-pharmacodynamic analysis to describe the increase in total plasma amyloid beta (Aβ) following treatment in patients with mild to moderate Alzheimer’s disease
Kenta Yoshida1, Anita Moein1, Tobias Bittner2, Lee Honigberg1, Jin Y Jin1, Angelica Quartino1
(1) Genentech, Inc., a member of the Roche Group, South San Francisco, CA, USA; (2) F. Hoffmann-La Roche AG, Basel, Switzerland.

P75: HGF is Associated with Decreased Subcortical Gray Matter and Hippocampal Volumes on MRI in Young and Middle-Aged Adults
Melaha R. Raman PhD1,2, Jayandra J. Himali PhD3,4, Sarah C. Conner MPH3,4, Charles DeCarli5 MD, Ramachandran S. Vasan, MD1,4, Alexis Beiser PhD1,2, Suda Seshadri MD6, Claudia L. Satizabal PhD2,4
(1) Department of Neurology, Boston University School of Medicine, Boston, MA; (2) Framingham Heart Study, Framingham, MA; (3) Department of Biostatistics, Boston University School of Public Health, Boston, MA; (4) Department of Medicine, Boston University School of Medicine, Boston, MA; (5) Department of Neurology, University of California, Davis School of Medicine, Sacramento, CA.

P76: CSF and genetic biomarkers in MCI and AD subjects in J-ADNI for predicting future outcome.
Kazushi Suzuki1, Ryoho Ishara1, Atsushi Iwata1, Takeshi Iwatsubo1, Hiroyuki Arai1, Kenji Ishii1, Michio Senda1, Kengo Ito1, Takeshi Ikeuchi1, Ryozo Kuwano1, Hiroshi Matsuda1, for the Japanese ADNI
(1) The University of Tohoku, Tohoku, Japan; (2) Tohoku University, Sendai, Japan; (3) Tohoku Metropolitan Institute of Gerontology, Tohoku, Japan; (4) Institute of Biomedical Research and Innovation, Kobe, Japan; (5) National Center for Geriatrics and Gerontology, Obu, Japan; (6) Niigata University, Niigata, Japan; (7) National Center for Neurology and Psychiatry, Kodaira, Japan.

P77: Concordance between in vivo amyloid imaging and CSF AD biomarkers measured by the automated LUMIPULSE G assay platform
Anne M. Fagan, PhD; Julia Gray, BS; Courtney Sutphen, BS; Amane Orusakwe, BS; Gina Jerome, MS; CJ Traynham, PhD2, Manu Vandijck, MD2, Zijjena Vucetic, MD, PhD3; Ryan Gailey, MBA4; John Lawson, BS, MT (ASCP); Brian Gordon, PhD5; Tammie Benziniger, MD, PhD6, David Holtzman, MD; John C. Morris, MD
(1) Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; (2) Fujirebio Diagnostics, Malvern, PA, USA; (3) Fujirebio Europe NV, Ghent, Belgium; (4) Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA; (5) Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA; (6) Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
LBP39: Neuroimaging markers of cerebrovascular disease predict cognitive impairment, brain atrophy and dementia in a cohort of community dwelling elders
Tammy M. Scott PhD1,2, Rafeeqe A. Bhadelia MD1, and Inrin H. Rosenberg MD2
(1) Jean Mayer USDA Human Nutrition Research Center on Aging; (2) Friedman School of Nutrition Science and Policy; (3) Harvard Medical School

LBP40: Measurement of the kinetic behavior of newly generated BACE1-cleaved APP in the human central nervous system in Alzheimer’s disease: initial proof-of-concept
Robert J. Vassar, PhD1, Randall J. Bateman, MD2, Bruce W. Patterson, PhD1, Justyna A. Dobrowolska Zaharia, PhD
(1) Department of Cell & Molecular Biology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; (2) Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA

LBP41: High Serum Levels of Malondialdehyde and 8-OHdG are both Associated with Early Cognitive Impairment in Patients with Acute Ischemic Stroke
Jincai He1, PhD, Zhihua Liu1, Yuntao Liu1, Xinjie Tu1, Huiping Shen1, Huihua Qiu1, Huijun Chen1
(1) Department of Neurology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Robert A. Rissman, PhD1, Louise Monte, MS1, Floyd Sarsoza, BS1, Amanze Orusakwe, B.S.2, Manu Vandijck, MD1, Ryan Gailey, MBA4, John Lawson, B.S., M.T. (ASCP)3, CJ Traynham, PhD2, Zivjena Vucetic, MD, PhD2
(1) Department of Neurosciences, University of California, San Diego, School of Medicine; (2) Fujirebio Diagnostics, Malvern, PA, USA; (3) Fujirebio Europe NV, Ghent, Belgium; (4) Fujirebio US, Malvern, PA, USA

LBP43: Utility of Event Related Potentials in a Memory Disorders Clinic
Katherine Turk, MD1,2, Cheongmin Suh1, Prayerna Uppal1, August Price1,3, Ala’a El-Shaar MS1, Andrew E. Budson, MD1,2
(1) Center for Translational and Cognitive Neuroscience, VA Boston Healthcare System; (2) Department of Neurology, Boston University School of Medicine; (3) William James College

LBP44: Analysis of Sex/Genotype Interactions in Baseline EXPEDITION3 Data
Valerie Bruemmer, MD1, Helen M Hochstetter, PharmD1, Melissa Anna Maria Pugh, PhD, MS1, Sara Kollack-Walter, PhD1
(1) Eli Lilly and Company, Indianapolis, IN, USA

LBP45: Central laboratory validation and performance assessment of new automated Ab1-42 and Total tau immunoassays
Didier Pitsi, PharmD, PhD1, Joachim Vandroemme, PhD2, Walter Hofer, BSc3, Els Decoster, PhD2, Astrid Coppens, PharmD, DCP2
(1) BARC Global Central Laboratory, Ghent, Belgium; (2) CRI Medical Laboratory, Ghent, Belgium (3) CRI Medical Laboratory at the time of these experiments, Ghent, Belgium

LBP46: Application of the revised diagnostic criteria for the early stages of Alzheimer’s disease to the LipiDiDiet study population
Tobias Hartmann, PhD1,2, Kaj Blennow, PhD3,6, Pieter Jelle Visser, PhD4,6, Alina Solomon, MD, PhD2,3,6, Suzanne B Hendrix, PhD2,3,6, Mia Kivipelto, MD, PhD2,3,6, Hilkka Soininen, MD, PhD2,3,6 on behalf of the LipiDiDiet clinical study group
(1) Deutsches Institut für Demenz Prävention (DIDP), Medical Faculty, Saarland University, Homburg, Germany; (2) Department of Experimental Neurology, Saarland University, Homburg, Germany; (3) Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden; (4) Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; (5) Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, Maastricht, the Netherlands; (6) Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; (7) Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland; (8) Department of Clinical Geriatrics, NVS, Karolinska Institutet, Huddinge, Sweden; (9) Clinical Trials Unit, Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden; (10) Pentara Corporation, Salt Lake City, UT, USA; (11) Neurocenter, Department of Neurology, Kuopio University Hospital, Kuopio, Finland
P78: Short-term repeat cognitive testing and its relationship to hippocampal volumes in older adults
Kevin Duff PhD1, Jeff Anderson MD PhD2, Atul Mallhi MD PhD2, Kayla R. Suhrie BS1, Bonnie C. Allred Dalley BSI, Taylor J. Atkinson BA1, & John M. Hoffman MD1,3
(1) Center for Alzheimer’s Care, Imaging and Research, Department of Neurology, University of Utah, Salt Lake City, UT, USA (2) Department of Radiology, University of Utah, Salt Lake City, UT, USA (3) Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA

P79: Development and validation of a short version of the Amsterdam IADL Questionnaire: a potential functional outcome measure for clinical trials
Roos J Jutten, MSc1, Carel FW Peeters, PhD2, Sophie MJ Leijdesdorff, MSc3, Pieter Jelle Visser, MD, PhD4, Andrea B Maier, MD, PhD5,6, Caroline B Terwee, PhD7, Philip Scheltens, MD, PhD2, Sietske AM Sikkes, PhD2
(1) Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands (2) Department of Epidemiology & Biostatistics, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, The Netherlands. (3) Alzheimer Center Rotterdam, Erasmus Medical Center, Rotterdam, The Netherlands. (4) Alzheimer Center, School for Mental Health and Neuroscience, University Medical Center Maastricht, The Netherlands (5) MOVE Research Institute Amsterdam, Department of Human Movement Sciences, VU University of Amsterdam, The Netherlands (6) Department of Medicine and Aged Care, Royal Melbourne Hospital, University of Melbourne, Australia

P80: Expanding the Brief Assessment of Cognition (BAC-App) for assessment of cognition in aging: Preliminary normative data and sensitivity to subjective cognitive decline
Alexandra S. Atkins, PhD1, Anzalee Khan PhD2, Joan Stroescu PhD1, Kathleen A. Welsh-Bohmer PhD3, Brenda L. Plassman PhD4, Christopher Randolph, PhD5, John Harrison PhD6, Adam W. Vaught, PhD7, Dañela Balentin, MA1, Dean Holbert, BA1, Caty Hooks, MSW1, & Richard S.E. Keefe, PhD1
(1) inVivo Health, Somerset, New Jersey, United States (2) Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA (3) Harvard Medical School, Boston, MA, USA (4) Florey Institutes of Neuroscience and Mental Health, Melbourne, Australia (5) Melbourne School of Psychological Science, University of Melbourne, Australia

P81: Extracting digital biomarkers of sleep from 3-axis accelerometry using Deep Learning
Robin Woiz, PhD1, Janet Munro, MBBS MPhil MRCPsych, Ricardo Guererro, PhD2, Dereh Hill, PhD1, Yves Dauvilliers, MD PhD3
(1)Imperial College London, London, UK (2) Sleep Unit, Department of Neurology, Centre Hospitalier Universitaire, Montpellier, INSERM 1061, France

P82: Assessing the Potential of Patient Dependence Levels as a Treatment Outcome – Insights from EXPEDITION3
Daniel E. Ball, DrPH1, J. Scott Andrews, PharmD1, Wenyu Ye, PhD1, Ann M. Halte, MDs, Helen M. Hochstetler, PharmD1, Brandy R. Matthews, MD1, Kristin K. Wrobleski, PhD1
(1) Eli Lilly and Company, Indianapolis, IN

P83: Maximum Walking Speed, Physical Activity, and AD Biomarkers: Results from the Harvard Aging Brain Study
Dylan R. Kim, MPH1, Rachel Buchley, PhD1,4,6, Bernard Hanseewu1, Kathleen M. Klein6, Dorene M. Rentz, PsyD2, Reisa A. Sperling, MD MMS1,2,3, Keith A. Johnson, MD1,2,3,4
(1) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA (2) Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA (3) Harvard Medical School, Boston, MA USA (4) Florey Institutes of Neuroscience and Mental Health, Melbourne, Australia (5) Melbourne School of Psychological Science, University of Melbourne, Australia

P84: Providing Culturally Sensitive Training and Monitoring to Clinicians Administering Functional Assessments in Dementia Global Trials
Magdalena Perez1, Julie Marsh1, Chris Brady1, Patricia Belchter2, Isabelle Gelinas3, Christelle Giroudet4, Caroline Anfray4, Shuhong Zhao5
(1) inVivo Health, Somerset, New Jersey, United States (2) Centre de recherche Institut Universitaire de Geriatrie de Montreal, McGill University, Montreal, Quebec, Canada (3) Centre de recherche Interdisciplinaire en Readaptation du Montreal, McGill University, (4) MAP, Lyon, France

P85: Gaining Efficiencies in Prevention Trial Design: Sample Size Projections across Categorical and Continuous Cognitive Endpoints
Rebecca L. Koscielniak, PhD1, Erin M. Jonaitis, PhD1, Bruce P. Hermann, PhD1,2, Lindsay R. Clark, PhD3, Cindy M. Carlsson, MD, MS1,2, Sterling C. Johnson, PhD1
(1) Wisconsin Alzheimer’s Institute, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA (2) Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA (3) Geriatric Research Education and Clinical Center, Wm. S. Middleton Veterans Hospital, USA, Madison WI USA

Friday, November 3 and Saturday, November 4
Theme 5. Clinical trials: Cognitive and functional endpoints
Late Breaking Posters

**LBP47:** Exploring the Utility of the Digital Clock Drawing Test in Capturing Subtle Cognitive Changes and Biomarker Evidence at the Preclinical Stage of Alzheimer’s Disease
Dorene M. Rentz, PsyD1,2, Kathyrn V. Papp, PhD1,2,3, Irina Orlovsky, MA1, William Souillard-Mandara4, Dana Penney, PhD1,4, Randall Davis, PhD1,5, Keith A. Johnson, MD1,2,5
(1) Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA (2) Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA (3) Digital Cognition Technologies, Waltham, MA USA (4) Department of Neurology, Lahey Hospital and Medical Center, Burlington, MA, USA (5) Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA

**LBP48:** Clinical meaningfulness of Clinician’s Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) scale in relation to goal attainment in participants on cholinesterase inhibitors
Susan E Howlett, PhD1,2, Justin Stanley, BSc1, Helen Wong, MSc1, Arnold Mitnitski, PhD1,2, Kenneth Rochwood, MD1,2
(1) DCI Clinical Inc., Halifax, NS, Canada (2) Division of Geriatric Medicine, Dalhousie University, Halifax, NS Canada (3) Department of Pharmacology, Dalhousie University, Halifax, NS, Canada

**LBP49:** Assessment of iADL functioning in individuals with subjective cognitive decline using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)
Alexandra S. Atkins, PhD1,2,3, Justin Stanley, BSc1, Lauren Trottier, MS, CSP1, Kathryn V. Papp, PhD1,2,3, Justin Stanley, BSc1, Helen Wong, MSc1, William Souillard-Mandara4, Dana Penney, PhD1,4, Randall Davis, PhD1,5, Keith A. Johnson, MD1,2,5
(1)  Compass Research – BioClinica, Orlando, FL, USA (2) Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA (3) Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA (4) Digital Cognition Technologies, Waltham, MA USA (5) Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA

Theme 6. Cognitive assessment and clinical trials

**P86:** Longitudinal data modeling: an approach to enable the prediction of biomarker trajectories for Alzheimer’s disease
Neelsa Sood, MSc1,2, Sven Hodapp, MSc1, Anandhi Iyappan, M.Sc1,2, Marc Jacobs, PhD1, Prof. Martin Hofmann-Apitius1,2
(1) Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, Sanitär, Aachen, Germany (2) Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn-Aachen International Center for IT, Bonn, Germany

**P87:** Use of the CVLT-II as a pre-screening tool to reduce screen fails in MCI clinical trials.
Mariette Caial, PhD1, Lauren Trottier, MS, CSP1, Katherine Kruczetz, MS1, Pamela Voccia1, Kay Smith, MS, CSP1, Craig Curtis, MD1, Ira Goodman, MD1
(1) Compass Research – BioClinica, Orlando, FL, USA

**P88:** Enriching Participant Eligibility for Early AD Clinical Trials through Computerized Pre-Screening for Episodic Memory Deficit
Kenton Zavitz, Rosemary Abbott, Francesca Cormach, Pasquale Dente, Jennifer H Barnett
Cambridge Cognition, Cambridge, UK

**P89:** An Objective Clinical Vocabulary for the Temporal Unfolding of AD Biomarkers: Stages of Objective Memory Impairment
Ellen Grober, PhD1,2, Amy E. Veroff, PhD2,1
(1) Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA (2) Consultant, Bethesda, Maryland, USA

**P90:** Object and scene memory are differentially associated with CSF markers of Alzheimer’s Disease and MRI volumetry
David Berron1,2, Hartmut Schützel, Arturo Cardenas-Blanco2, Klaus Flessbach3, Michael Wagner1,2, Annika Spotthke1, Martin Reuter1,2, Stefan Teipel1,2,3, Katharina Bürger2,4, Schneider, Anja5,6, Oliver Peters1,2, Peter Nestor2, Josef Priller2,3, Jens Wiltfang1,2, Christoph Laske1,2, Frank Jessen1,2, Emrah Düzel1,2, and the DELCODE consortium
(1) Institute of Cognitive Neurology and Dementia Research, Otto von Guericke University Magdeburg, Germany (2) German Center for Neurodegenerative Diseases Magdeburg, Germany (3) Institute of Cognitive Neuroscience, University College London, United Kingdom (4) Department of Psychiatry, University Hospital Bonn, Bonn, Germany (5) German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany (6) Department of Psychosomatic Medicine, University Medicine Rostock; Rostock, Germany (7) German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany (8) Department of Psychiatry, University of Cologne, Cologne, Germany (9) Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität (LMU), Munich, Germany (10) German Center for Neurodegenerative Diseases (DZNE), Munich, Germany (11) Department of Psychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany (12) German Center for Neurodegenerative Diseases (DZNE) Berlin, Germany (13) Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany (14) German Center for Neurodegenerative Diseases (DZNE), Götingen, Germany (15) Department of Psychiatry and Psychotherapy, Eberhard Karls University Tübingen, Tübingen, Germany (16) German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany (17) Department of Radiology, Harvard Medical School, Boston, USA (18) Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, Cambridge, USA
CTAD 2017

**POSTER PRESENTATIONS**

**Friday, November 3 and Saturday, November 4**

**P91:** Effectiveness of Rater Training and Data Surveillance in Alzheimer’s Disease (AD) Clinical Trials  
Rolana Avrumson, MS1, Melissa A. Carbo, MS2, Henry J. Riordan, PhD2, Michael F. Murphy, M.D., PhD2, Neal R. Cutler, M.D.1  
(1) WorldWide Clinical Trials, Beverly Hills, CA (2) WorldWide Clinical Trials, King of Prussia, PA

**P92:** Diagnostic value of a cognitive battery for assessing cognitive decline  
A. Nidos1, D. Kasselimis2, K. Zavitz3, F. Cormack1  
(1) Neurological Clinic – Department of Neuropsychology, Metropolitan Hospital (2) 1st Neurology Department, National and Kapodistrian University of Athens (3) Cambridge Cognition

**Late Breaking Posters**

**LBP50:** Breadth and Depth of Working Memory and Executive Function Impairment in Mild Cognitive Impairment  
Terry E. Goldberg, PhD1 and Jesus Gomar, PhD2  
(1)Genetic Psychiatry, Columbia University Medical Center, NYC, NY (2)L. I. Swin Zucher Alzheimer’s Center, Manhasset, NY

**LBP51:** The Early AD/ MCI Alzheimer’s Cognitive Composite (EMACC): Development and preliminary validation across four longitudinal cohorts of a cognitive endpoint for clinical trials in the MCI and Early AD stage of disease.  
Judith Jaeger, PhD2, Clint Hagen, MS2, Hennhil Loft, PhD2, Yen Ying Lim, PhD2, Andrew Aschenbrenner, PhD2, Marta Segerdahl, MD, PhD2, Gary Tong, MD, PhD2, Michelle Mielke, PhD2, Jason Hassenstab2, PhD2, Nitthr Stricker, PhD2  
(1)Albert Einstein College of Medicine, Bronx, NY and CognitionMetrics, LLC, Wilmington, DE, USA (2)Mayo Clinic, Rochester, MN, USA (3)H. Lundbeck A/S, Valby, Denmark (4) The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia (5) Washington University in St. Louis, St. Louis, MO

**LBP52:** A comparison of in-person and web-based computerised cognitive testing using CANTAB  
Francesca Cormack1, Rosa Bachx1, Jack Cotter1, Nich Taptitilisi1, Lucie de Coch1, Kenton Zavitz1, Jennifer H. Barnett1  
(1) Cambridge Cognition, Cambridge, UK (2) Department of Psychiatry, University of Cambridge, UK

**LBP53:** Automated voice-based testing: applications in recruitment of patients in clinical trials  
Nich Taptitilisi1, Francesca Cormack PhD2, Jennifer H Barnett PhD2  
(1) Cambridge Cognition, Cambridge, UK (2) Department of Psychiatry, University of Cambridge, UK

**LBP54:** Use of the International Shopping List Test as the objective assessment of cognitive impairment to identify subjects with early Alzheimer’s disease in the Eisai elenbecestat MissionAD phase 3 clinical trials  
Bruce Albala, PhD1, Michelle Gee, PhD2, Adrian Schembri, PsyD3, Paul Maruff, PhD1  
(1) Eisai Inc., Woodcliff Lake, New Jersey, USA (2) Eisai Ltd, Hatfield, UK (3) Cogstate Ltd, Melbourne, Australia

**LBP55:** Assessing risk factors for cognitive impairment in patients with diabetes  
Martin Rakusa, MD, PhD1, Matej Rakusa, MD, Miro Cokolic, MD2  
(1) Department of Endocrinology and Diabetes University Medical Centre Maribor, Maribor, Slovenia, 2) Department of Neurology University Medical Centre Maribor, Maribor, Slovenia

**LBP56:** PRELIMINARY FINDINGS OF APTEST: A PRESCREENING TOOL DEMONSTRATING INITIAL PREDICTIVE AND DIAGNOSTIC IMPLICATIONS.  
Pamela Voccia, Ed.S.1, Katherine Kruyczet, M.S.1, Joy Kettren, M.S.1, Jennifer Cody, B.S.2, Nichole Stiivin, B.A.3  
(1) Bioclinica Research, The Villages, Florida, USA

**LBP57:** Psychometric Properties of the Imprint Eye Tracking Memory Assessment: Internal, Test-Retest and Alternate Forms Reliability  
Nicholas T. Bott, PsyD2, Alex Lange, MS3, Robert Cosgriff, MS2, Paul Clopton, MS2, Beth Buiffo, PhD2, Stuart Zola, PhD2, Claudia Y. Santos BS6, Peter Snyder, PhD2  
(1) Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA (2) Neurotech Technologies, Inc., Redwood City, California, USA (3) University of California San Diego School of Medicine, San Diego, California, USA (4) University of Washington, Seattle, Washington, USA (5) Emory University Office of the Provost, Atlanta, Georgia, USA (6) Interdisciplinary Neurosciences Program, University of Rhode Island, Kingston, RI, U.S.A. (7) Lifespan Clinical Research Center, Rhode Island Hospital, Providence, RI, USA. (8) Department of Neurology, Alpert Medical School of Brown University, Providence, RI, USA.

**LBP58:** Utility of the International Shopping List Test for detection of memory impairment associated with prodromal and early Alzheimer’s disease in clinical trials  
Paul Maruff, PhD1, Adrian Schembri, PsyD1, Shau Yu Lynch, PhD1, Bruce Albala, PhD1  
(1) Cogstate Ltd, Melbourne, Australia (2) Eisai Inc., Woodcliff Lake, New Jersey, USA
LBP59: DCTclock metrics correlate with neuroimaging biomarkers among those with AD genetic risk
Braydon Schaible, William Souillard-Mandar, Randall Davis, Rhoda Au, Dana Penney
(1) Digital Cognition Technologies, Inc, Waltham, MA, USA, (2) MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA (3) Boston University Schools of Medicine and Public Health, Boston, MA, USA (4) Lahey Hospital and Medical Center, Burlington, MA, USA

Theme 7. Behavioral disorders and clinical trials

P93: Lumateperone (ITI-007), a novel drug in development for the Treatment of Agitation in Patients with Dementia, Including Alzheimer’s Disease: Rationale and Clinical Trial Design
Robert Davis Ph.D.1, Kimberly Vanover Ph.D.1, Cedric O’Gorman MD1, Jelena Saillard1, Michal Weingart Ph.D.1, Sharon Mates Ph.D.1

P94: Alzheimer's Disease Cooperative Study (ADCS) Multicenter Trial: Prazosin for Agitation in Alzheimer’s Disease (PEACE-AD)
Elaine R. Peskind, MD1,2, Murray A. Raskind, MD1,2, Howard Feldman, MD, FRCPC1, for the Alzheimer’s Disease Cooperative Study
(1) VA Puget Sound Health Care System, Mental Illness Research, Education and Clinical Center (MIRECC), Seattle, WA, USA (2) University of Washington, Department of Psychiatry and Behavioral Sciences, Seattle, WA, USA (3) Alzheimer’s Disease Cooperative Study, San Diego, CA, USA (4) University of California, San Diego, Department of Neurosciences, San Diego, CA, USA Alzheimer’s Disease Cooperative Study (ADCS)

P95: Neuropsychiatric symptoms and the risk of conversion to dementia among MCI subjects
Maria Soto, MD, PhD1, Simon Dietlin, MD, Vera Kiyasova PhD2, Maria Pueyo, MD, PhD2, Adelaide de Mauléon, MD, Julien Delrieu, MD, Pierre Jean Ousset, MD1, Bruno Vellas, MD, PhD1
(1) Gerontopôle, INSERM U 1027, Alzheimer’s Disease Research and Clinical Center, Toulouse University Hospital, France (2) Institut de Recherches Internationales Servier, Suresnes, France

P96: Natural History, Epidemiology, Neurobiology, Burden, and Unmet Needs of Agitation in Alzheimer’s Disease: Where are we now? A Systematic Review
Chuidian M1, Waterman F1, Bird S1, De Jong-Laird A1, Baker R1, Mejerian T1
(1) Avanir Pharmaceuticals Inc, Aliso Viejo, CA (2) Xcenda, Palm Harbor, FL (3) Otsuka Pharmaceutical Europe Ltd (OPEL), Gallions, Wexham Springs (4) Otsuka Pharmaceutical Development and Commercialization, Inc (OPDC), Princeton, NJ

Late Breaking Posters

LBP60: Donepezil treatment in patients with depression and cognitive impairment on stable antidepressant treatment: a randomized controlled trial
Davangere P. Devanand, MD1, Gregory H. Pelton, MD2, Kristina D’Antonio, MSW3, Adam Ciarleglio, PhD4, Jennifer Scodes, MS5, Howard Andrews, PhD5, Julia Lumsford, MD6, John L. Beyer, MD7, Jeffrey R. Petrella, MD8, Joel Sneed, PhD9, P. Murali Doraiswamy, MDF
(1) Geriatric Psychiatry & Department of Psychiatry, Columbia University, New York, NY, USA (2) Geriatric Psychiatry & Department of Psychiatry, Columbia University, New York, NY, USA (3) Biostatistics, Department of Psychiatry, Columbia University, New York, NY, USA (4) Biostatistics, Department of Psychiatry, Columbia University, New York, NY, USA (5) Biostatistics, Department of Psychiatry, Columbia University, New York, NY, USA (6) Department of Radiology, Duke University, Durham, NC, USA (7) Department of Psychiatry, Duke University, Durham, NC, USA (8) Department of Psychology, Queens College, City University of New York, New York, NY, USA (9) Department of Psychiatry, Duke University, Durham, NC, USA

LBP61: Memantine ER With an AChEI Improves Individual SIB Scores Compared With AChEI Alone: Post Hoc Analyses From a Randomized, Double-blind, Placebo-controlled Study
George Crossberg, MD1, Ken Kramer, PhD2, Suzanne Hendrix, PhD2, Noel Ellison, MS3, Majid Kerolous, PharmD, MPH2
(1) Saint Louis University, Saint Louis, MO, USA (2) Allergan, Jersey City, NJ, USA (3) Pentara Corporation, Salt Lake City, UT, USA

LBP62: Using Radio Signal-based Sensing and Machine Learning for Continuous Longitudinal Monitoring of Behavioral Symptoms in Dementia: A Pilot Case Study
Ipsit Vahia, MD1, Zachary Kabelac, MEng2, Chen-Yu Hsu, MS3, Rumen Hristov, MEng2, Patrick Monette, BS4, David Harper, PhD5, William McGrory, LCWS6, Brent Forester, MD1, Dina Katabi, PhD2
(1) Division of Geriatric Psychiatry, McLean Hospital/Harvard Medical School, Belmont, MA, USA, (2) Computer Science and Artificial Intelligence Lab (CSAIL), Massachusetts Institute of Technology (MIT), Cambridge, MA, USA, (3) Robbie’s Place Assisted Living, Marlborough, MA
Friday, November 3 and Saturday, November 4

**Theme 8. Health economics and clinical trials**

**P97: Cost of illness and economic burden of early Alzheimer’s disease: a systematic review**
Richard Lawson, MSc1, Weiguang Xue, MSc2, Adam Lloyd, MPhiP, Christina-Jane Crossman-Barnes, MSc3, Rebekah Fong, MSc4
[1] AstraZeneca, US (2) QuintilesIMS, UK (3) University of East Anglia, UK

**P98: Challenges in Optimising Real World Evidence for Alzheimer’s Disease**
Catherine Reed, PhD1; Frederic de Reydet de Vulpillieres, MSc2, John Gallacher, PhD3, and the ROADMAP consortium

**P99: Dependence Scale to Assess the Cost-Consequences of Alzheimer’s Disease Treatments**
Joshua A. Roth, PhD, MHA1; Joshua T. Cohen, PhD2; Peter J. Neumann, ScD3, Carolyn W. Zhu, PhD3, Yaakov Stern, PhD4, Sean D. Sullivan, PhD5
[1] Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA (2) Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA (3) Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN (4) Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York, NY, USA (5) Department of Pharmacy, University of Washington, Seattle, WA, USA

**Late Breaking Posters**

**LBP63: Review of clinical guidelines on use of antipsychotic drugs in the treatment of behavioral symptoms in dementia and their impact on patient outcomes**
Myrlene Sanon Aigbogun, MPH1; Milena Anatchkova, PhD2; Anne Brooks, BS3; Laura Swett, PhD2; Ann Hartry, PhD3; Ruth A. Duffy, PhD4; Ross A. Baker, PhD5

**LBP64: The Natural Progression of Agitation in Alzheimer’s Disease/Dementia: A Systematic Literature Review**
Milena Anatchkova, PhD1; Anne Brooks, BS2; Laura Swett, PhD2; Ann Hartry, PhD3; Ruth A. Duffy, PhD3; Ross A. Baker, PhD4; Myrlene Sanon Aigbogun, MPH4

**Theme 9. Epidemiology and clinical trials**

**P100: Prevalence and progression of preclinical and prodromal AD among non-demented persons in a population-based setting**
Rosebud O. Roberts, MB ChB, MS1,2; Jeremiah A. Aahre, MPH3; Walter K. Kremers, PhD3; Maria Vassilahi, MD, PhD; Michelle M. Mielke, PhD4; David S. Knopman, MD2; Jonas E. Geda, MD, MSc1,4; Preciosa Coloma, MD, PhD5; Barbara Schaubie, MD, PhD6; Val J. Lowe, MD7; Clifford R. Jack Jr., MD7; Ronald C. Petersen, MD, PhD1,2
[1] Department of Health Sciences Research, Mayo Clinic, Rochester, MN (2) Mayo Clinic, Rochester, MN (3) Department of Health Sciences Research, Division of Biomedical Sciences, Mayo Clinic, Rochester, MN (4) Departments of Psychiatry and Neurology, Mayo Clinic, Rochester, MN (5) Departments of Psychiatry and Neurology, Mayo Clinic, Rochester, MN (6) Medical Affairs, F. Hoffmann-La Roche Ltd, Basel, Switzerland (7) Department of Radiology, Mayo Clinic, Rochester, MN

**P101: Lipophilic Versus Hydrophilic Statin Exposure and Post-Mortem Neuropathological Findings in the NACC Autopsy Cohort**
Aaron M. Koenig MD1; Jing Qian PhD2; Rebecca A. Betenshy PhD2; Steven E. Arnold MD1
[1] Department of Neurology, Massachusetts General Hospital, Boston, MA, USA (2) Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts, Amherst, MA, USA (3) Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
Friday, November 3 and Saturday, November 4

P102: The longitudinal association of glycemic control based on glycemic target of the JDS/JGS joint committee with cognitive and ADL decline in patients with MCI and AD.
Taiki Sugimoto, RPT, MSc1,2,3,4, Taihaki Suhuri, MD, PhD1,5, Ai Kimura, RD, MSc2,4, Reo Ono, RPT, MPH, PhD1, Naoki Saji, MD, PhD1, Shumpei Niida, PhD1, Kenji Toba, MD, PhD1
(1)Center for Comprehensive Care and Research on Memory Disorders, National Center for Geriatrics and Gerontology, Obu, Japan (2) Medical Genome Center, National Center for Geriatrics and Gerontology, Obu, Japan (3) Department of Community Health Sciences, Kobe University, Graduate School of Health Sciences, Kobe, Japan (4) Japan Society for the Promotion of Science, Tokyo, Japan (5) Department of Cognitive and Behavioral Science, Nagoya University, Graduate School of Medicine, Nagoya, Japan

P103: Clinical Attributes and Disease Progression among Patients with Mild Cognitive Impairment Associated with Alzheimer’s disease: Findings from the National Alzheimer’s Coordinating Center
J. Scott Andrews, PharmD1, Urvi Desai, PhD2, Noam Y. Kirson, PhD2, Miriam Zichlin, MPH2, Sophie Schonfeld, BA2, Daniel E. Ball, DrPH1, Colin Green, PhD3
(1) Eli Lilly and Company, Indianapolis, IN (2) Analysis Group, Inc., Boston, MA (3) University of Exeter, Exeter, UK

P104: The association between body mass index and cognitive decline in patients with small vessel disease -preliminary study
Hae-Eun Shin, Seong-Hoon Kim, Si Baek Lee, Jung-Wook Park
The Catholic University of Korea, Uijeongbu, South Korea

P105: Nutritional status in patients with MCI, AD and DLB and its clinical meaning for dementia prevention and care.
Ai Kimura, RD, MSc1,2,3,4 Takashi Suhuri, MD, PhD1,5 Taiki Sugimoto, RPT, MSc2,4, Kazuya Kitamori, RD, PhD1, Naoki Saji, MD, PhD1, Shumpei Niida, PhD1, Kenji Toba, MD, PhD1
(1)Center for Comprehensive Care and Research on Memory Disorders, National Center for Geriatrics and Gerontology, Obu, Japan (2) Medical Genome Center, National Center for Geriatrics and Gerontology, Obu, Japan (3) Department of Cognitive and Behavioral Science, Nagoya University, Graduate School of Medicine, Nagoya, Japan (4) Department of Community Health Sciences, Kobe University, Graduate School of Health Sciences, Kobe, Japan (5) Japan Society for the Promotion of Science, Tokyo, Japan (6) College of Human Life and Environment, Kinjo Gakuin University, Nagoya, Japan

P106: Optimizing Dietary Intervention Studies of Modifiable Risk Factors and Comorbidities for Late Onset Alzheimer’s Disease
Feng-Yen Li, PhD1 and Ann Lam, PhD2
(1) Physicians Committee for Responsible Medicine, Washington, DC, USA (2) Green Neuroscience Laboratory, Neurolinx Research Institute, San Diego, CA, USA

P107: Is the time right to capitalise on emergence of Lifetime and Lifestyle Alzheimer’s disease Related Factors as Determinants of pre-disease Neurocognitive Performance? Cross-sectional evidence from the CHARIOT PRO Main Study
Chinedu T Udeh-Momoh, PhD1 Bowen Su MD1, Geraint J Price, DClinPsych1, David Muller, PhD1, Darina Bassil, MPH1, Catherine Robb, MSc1, Heather Ward, PhD1, Michael T. Ropach, PhD1,4, Robert Pernecky, MD2, Ioanna Tzoulaki, PhD1, Ida Leffros T Middleton, MD1
(1) Imperial College London, London, United Kingdom (2) Ludwig-Maximilians-Universität, Munich, Germany (3) Janssen Research and Development, Fremont, CA, USA (4) Loma Linda University School of Medicine, Loma Linda, CA, USA (5) MedAvante, Inc., Hamilton, NJ, USA

P108: Clinical trial recruitment rate from a patient data base in an academic geriatric center
Daniel G. Gámez Treviño, Blanca I. González García, Patricia A. Guerrero Garza, Ricardo Salinas Martínez
Geriatric Services, “Dr. Jose Eleuterio González” University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Nueva León, México.
Friday, November 3 and Saturday, November 4

Theme 10. Clinical Trials: Animal Models

**P109:** Nanodelivery of Cerebrolysin reduces phosphorylated tau and prostaglandin metabolite F-2 isoprostane in CSF and brain in Alzheimer’s disease. Novel therapeutic strategies using nanomedicine

Aruna SHARMA1, José V LAFUENTE2, Dafin F MURESANU3, Rudy J CASTELLANI4, Mark A SMITH5, Ranjana PATNAIK6, Z Yan TIAN7, Asya OZKIZILCIK8, Herbert MÖSSLER9, Hari S SHARMA1

(1) International Experimental CNS Injury & Repair (IE CNSIR), Laboratory of Cerebrovascular Research, Uppsala University Hospital, Uppsala University, Uppsala, Sweden (2) Dept of Neurosciences, University of Basque Country, Bilbao, Spain (3) Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania; aRoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania (4) University of Maryland, Baltimore, MD, USA (5) Case Western Reserve Medical University, Cleveland, OH, USA (6) School of Biomedical Engineering, Indian Institute of technology, Banaras Hindu University, Varanasi, India (7) Dept. Chemistry & Biochemistry & Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA (8) Ever NeuroPharma, Oberburgau, Austria

**P110:** Nanodelivery of Cerebrolysin potentiates histamine antibodies and histaminergic H3 and H4 receptor modulation induced reduction in brain pathologies in Alzheimer’s disease.

Hari Shanker SHARMA1, José V LAFUENTE2, Dafin F MURESANU3, Rudy J CASTELLANI4, Mark A SMITH5, Ranjana PATNAIK6, Z Yan TIAN7, Asya OZKIZILCIK8, Stephen D SKAPER, Herbert MÖSSLER9, Aruna SHARMA1

(1) International Experimental CNS Injury & Repair (IE CNSIR), Laboratory of Cerebrovascular Research, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden (2) Dept of Neurosciences, University of Basque Country, Bilbao, Spain (3) Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania; aRoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania (4) University of Maryland, Baltimore, MD, USA (5) Case Western Reserve Medical University, Cleveland, OH, USA (6) School of Biomedical Engineering, Indian Institute of technology, Banaras Hindu University, Varanasi, India (7) Dept. Chemistry & Biochemistry & Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA, (8) University of Padua, Faculty of Medicine, Padua, Italy (9) Ever NeuroPharma, Oberburgau, Austria

**P111:** Can the use of approved imaging compounds also be used a therapy in Alzheimer’s Dementia

James Fontanesi MD1; Daniel B Michael MD1; Alaa Hanna MD1; Michael Maddens MD1; Pratosh Chinaliyan2; Giovanni Fontanesi2; Thomas Wilson1; Alvaro Martinez MD3; Katie Buelow1; Barbara Pruett1; George D Wilson Ph.D1

(1) William Beaumont Health Systems (2) Oakland University, Rochester, MI, USA (3) 21st Century Oncology, Farmington Hills, MI, USA

**P112:** Inhibition of Caspase-1 as a novel treatment against age-dependent cognitive decline and Alzheimer Disease

Andrea C. LeBlanc1,2, Joseph Flores1

(1) Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada (2) Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada

**P113:** Combination radiation techniques may play a role in the treatment of Alzheimer’s Dementia

James Fontanesi MD1; Daniel B Michael MD1; Michael Maddens1; Alaa Hanna MD1; Thomas G Wilson BS1; Giovanni Fontanesi2; Pratosh Chinaliyan MD1; Alvaro Martinez MD3; Katie Buelow1; George D Wilson Ph.D1

(1) William Beaumont Health Systems (2) Oakland University, Rochester, MI, USA (3) 21st Century Oncology, Farmington Hills, MI, USA

Late Breaking Posters

**LBP13:** SUVN-502 potentiates the preclinical pharmacological activities of current standards-of-care for Alzheimer’s disease.

Ramakrishna Nirogi, PhD1, Vijay Benade MS1, Renny Abraham, PhD1, Gopinadh Bhyrapuneni, PhD2, Jyothsna Ravula, MS1, Koteshwara Mudigonda, PhD3, Devender Reddy Ajiala,PhD4, Ramasastry Kambhampati, Phd5, Anil Shinde, PhD6 and Venkat Jasti MS1

(1) Discovery Research, Suven Life Sciences Ltd, Hyderabad, India

**LBP14:** The PDE4-inhibitor rolflumilast improves memory: findings from a translational perspective

Arian Blokland, PhD1, Wim Riedel, PhD2, Marlies Van Duinen, PhD2, Ante Sambeth, PhD2, Pim Hechman, PhD2, Max Tsai, PhD2, Gezim Lahu, PhD3, Tolga Uz, MD, PhD1, Jos Prichaerts, PhD2

(1) Department of Neuropsychology and Psychopharmacology, Maastricht University, Maastricht, The Netherlands (2) Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands (3) Ta hedah Development Center, Taheada, Deerfield, USA (4) Ta hedo Pharmaceuticals Internatio nal, Taheada, Zurich, Switzerland
CTAD 2017 would like to thank its privileged partners for their continued support of CTAD.

Gold Sponsors
Breakfast for people staying at the Boston Park Plaza in the CTAD Block: Information will be handed to you upon check-in regarding breakfast location for each day of your stay.

Registration Information (no onsite registration)

Pre-registration:
Avoid the rush and come pick-up your conference materials on **Wednesday, November 1** starting at 1pm.

Registration desk opening hours:
- Thursday, November 2 from 7:30 am to 6 pm
- Friday, November 3 from 7:30 am to 5:30 pm
- Saturday, November 4 from 7:30 am to 4:30 pm
Conference Room:
All sessions will be held in Grand Ballroom A and B (Mezzanine level)

Coffee Breaks and Poster Sessions:
Georgian Room and Ballroom Foyer (Mezzanine level)

Lunches*:
(only for attendees who purchased the lunch package) in ABC rooms (Mezzanine Level) please present your badge at the entrance.
*No possibility of buying lunches onsite

Speaker Ready Room - Preview room - Hours of Operation
• Wednesday, November 1: 1 pm–6 pm
• Thursday, November 2: 7:30 am–6 pm
• Friday, November 3: 7:30 am–6 pm
• Saturday, November 4: 7:30 am–4 pm

POSTER SESSIONS
All the necessary material will be available onsite to display your poster

Wednesday, November 1 and Thursday, November 2
Poster set-up: Wednesday, November 1 starting at 1pm
Poster take-down: Thursday, November 2 no later than 6pm

Theme 1. Clinical trials: Methodology - P1 to P25 and LBP1 to LBP12
Theme 2. Clinical trials: Results - P26 to P42 and LBP25 to LBP32
Theme 11. New therapies and clinical trials - P114 to P129 and LBP15 to LBP24

Friday, November 3 and Saturday, November 4
Poster set-up: Friday, November 3 starting at 7:30 am
Poster take-down: Saturday, November 4 no later than 5pm

Theme 3. Clinical trials: Imaging - P43 to P55 and LBP35 to LBP38
Theme 4. Clinical trials: Biomarkers including plasma - P56 to P77 and LBP39 to LBP46
Theme 5. Clinical trials: Cognitive and functional endpoints - P78 to P86 and LBP47 to LBP49
Theme 6. Cognitive assessment and clinical trials - P87 to P92 and LBP50 to LBP59
Theme 7. Behavioral disorders and clinical trials - P93 to P96 and LBP60 to LBP62
Theme 8. Health economics and clinical trials - P97 to P99 and LBP63 to LBP64
Theme 9. Epidemiology and clinical trials - P100 to P108
Theme 10. Clinical Trials: Animal Models - P109 to P113 and LBP13 to LBP14
CTAD 2017 has its own Mobile App!

The App will be available for download on October 28, 2017 on the Apple App Store and Google Play (search CTAD17) to be used on your mobile phone but also on larger devices like an iPad or a desktop.

The conference is right at your fingertips: discover the program, read the abstracts, learn more about our speakers, network with other participants and so much more!

Get in touch

CTAD BOSTON 2017
CTAD Congress
Phone: +33 4 67 10 92 23
Email: ctad@ant-congres.com
www.ctad-alzheimer.com

Follow us on

@CTAD2017  CTAD Alzheimer  CTAD Conference

#CTAD17

www.ctad-alzheimer.com
October 24-27, 2018
BARCELONA

www.ctad-alzheimer.com